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Abstract 
Introduction: Brain-derived neurotrophic factor (BDNF) is essential for neurogenesis and synaptic 
plasticity, which are important in memory, particularly in neurons in the prefrontal cortex and 
hippocampus. Declining BDNF levels have been suggested to contribute to cognitive ageing, which 
in the context of a globally ageing population, needs to be investigated further, particularly in 
regards to underlying epigenetic regulation. 
Methods: We investigated BDNF and cognitive ageing in the MyoAge population, which consisted 
of cognitively healthy young (n=135, 23.4 ± 2.7 years) and older (n=226, 74.5 ± 3.4 years) adults. 
Cognitive function had previously been tested using CANTAB. Investigation of BDNF and 
Alzheimer’s disease was performed in the Dyne-Steele cohort (n=67). Bisulfite pyrosequencing 
was used to quantify BDNF methylation. Genotyping was performed on the BDNF Val66Met 
polymorphism. RT-PCR was used to quantify BDNF gene expression. Chromatin 
Immunoprecipitation and subsequent allele discrimination via pyrosequencing was used to 
determine gene-environment interactions. 
Results: In the MyoAge cohort, we observed that BDNF exon I methylation is associated with 
cognitive decline in the male population, with higher BDNF exon I methylation associated with 
worse executive functioning and working memory capacity in the old males (P=0.001, P=0.011, 
respectively). Physical activity was associated with reduced methylation of BDNF exon IV in the 
older females (P=0.033). Early life education is associated with reduced BDNF methylation in the 
older adults. In the Dyne-Steele cohort, BDNF exon I expression was associated with faster rates 
of memory decline in the AD group. BDNF exon I methylation was associated with BDNF gene 
expression in the healthy group, but not the AD group. Histone H3K27ac marker bound more 
readily to the BDNF rs56133711 A allele. 
Discussion: These results suggest that BDNF methylation is associated with cognitive decline in 
the older population. Lifestyle factors play a significant role in BDNF methylation and should be 
considered with further investigation of BDNF methylation and cognitive ageing. BDNF could act 
to compensate AD damage, however AD neuropathology appears to interfere with epigenetic 
regulation of BDNF. 
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1. Introduction 
1.1 Ageing 
In the past half century, ageing has emerged as one of the key policy issues of 
governments and organisations across the globe. This was highlighted by the production 
of international legal and policy framework by the United Nations General Assembly 
(United Nations, 2002) and The World Health Organisation (WHO, 2012), separately. The 
WHO (WHO, 2012) noted the challenges ahead, including the increased risk of disability 
with age and the increased need for provision of care to ageing populations, while 
proposing policy to combat this. Their health specific policy called for the prevention and 
reduction of the burden of excess disabilities, chronic disease and premature mortality, as 
well as a reduction of risk factors associated with major diseases while increasing factors 
that protect health throughout life. 
However, the most recent World report on ageing and health (WHO, 2015), emphasised 
that there is still not enough being done to ensure that these policies are being 
implemented to a satisfactory level. Moreover, with the increased global situation of 
ageing (Figure 1.1), the challenge to combat the issues associated with an ageing 
population is becoming increasingly more complex. 
12 
 
 
Figure 1.1. The proportion of the global population aged 60 years or older in 2015, based on data from 
individual countries, in comparison to 2050 projections. Figure was adapted from the ‘World report on 
ageing and health’ (WHO, 2015). 
1.2 Age-related cognitive decline 
Ageing is the lifelong accumulation of molecular and cellular damage, which eventually 
overcomes the mechanisms and safeguards working within the body to repair damage 
and remove waste products. The increasing imbalance gradually impairs and damages the 
systems required for healthy function, resulting in dysfunction, disease and ultimately 
death (Kirkwood, 2008). Cognitive function is one such system that is notoriously linked 
to ageing. It has been difficult to accurately determine the rate at which cognitive decline 
13 
 
will affect populations, mainly due to the inconsistent definitions that are supposed to 
separate normal brain ageing from the various stages of dementia onset (Sachdev et al, 
2015). Moreover, the multifactorial nature of the phenomenon, including the impact of 
lifestyle factors for example, will need to be considered.  
Cognitive ageing puts the elderly at risk of various impairments to quality of life, including 
social isolation and abuse (WHO, 2015). However, potentially the most detrimental risk of 
ageing and its associated cellular mechanisms is neurodegeneration (Alzheimer’s 
Association, 2017). Therefore, with the current predictions of an increasingly ageing 
population, there should be concern for the ensuing burden of neurodegenerative 
disease. 
1.3 Dementia 
Dementia is a syndrome that affects the ability for someone to live a normal life, it is 
characterised by loss of memory and other cognitive abilities that are essential for 
everyday functioning. Of all the brain abnormalities that are defined under dementia, 
Alzheimer’s disease (AD) is the most prevalent (Alzheimer’s Association, 2017). AD is 
association of the accumulation of β-amyloid plaques and neurofibrillary (tau) tangles, 
which have been implicated in the interference of neuronal signalling and death.  
The neuropathology of AD has been suggested to begin 20 years before clinical 
observations (Villemagne et al, 2013). This emphasises the potential cross-over with 
cognitive ageing, and with no successful treatments to reverse or alter the progression of 
AD, full understanding of this link in countering the growing global burden is essential. 
This should include the development of an advanced biomarker framework (Dubois et al, 
2014). 
1.4 Mechanisms involved in age-related cognitive decline 
It is still uncertain to what extent current knowledge covers the processes involved in age-
related cognitive decline, there are clearly missing pieces to the puzzle, but conversely 
significant discoveries have been and are being included into mechanistic pathways. 
Structurally, various reductions in synaptic density, including in the hippocampus and 
prefrontal cortex, important in memory and executive function, manifest with age 
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(Petralia et al, 2014), as well as atrophy within the above areas (Apostolova et al, 2012) 
and across the brain (Erten-Lyons et al, 2013). Adult neurogenesis, important for the 
formation of new memories such as in fear conditioning and spatial learning, decreases in 
an age-related manner (Seib and Martin-Villalba, 2015). 
While cognitive ageing and AD are distinct conditions, the similarities are notable, from 
the atrophy or damage to the neurons associated in memory, such as in the prefrontal 
cortex. Therefore there may be underlying mechanisms that contribute to the 
progression of these disorders in similar ways. 
1.5 BDNF 
Brain-derived neurotrophic factor (BDNF) is a highly potent neurotrophin that promotes 
neurogenesis, synaptic plasticity and long-term potentiation (LTP) in the CNS (Barde et al, 
1982; Kang and Schuman, 1995; Figurov et al, 1996). It binds with high affinity to the 
transmembrane tropomyosin-related kinase receptor (TrkB) on neurons and glia (Yan et 
al, 1997) which initiates downstream signalling cascades, including phosphoinositide 3-
kinase (PI3K), mitogen-activated protein kinase (MEK), and phospholipase C-γ (PLC-γ) 
associated pathways (Figure 1.2).  Together, they promote further transcription, synaptic 
plasticity, protein-synthesis dependent plasticity, cell survival and neurogenesis (Yoshii 
and Constantine-Paton, 2010). 
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Figure 1.2 BDNF-TRKB downstream signaling cascade. Taken from Duman and Voleti (2012). 
1.6 BDNF gene 
The BDNF gene (Figure 1.3), on chromosome 11p13 (Maisonpierre et al, 1991), contains 
at least 9 functional promoters and 11 exons (Pruunsild et al, 2007). BDNF exon IX is the 
3’ coding exon which is alternatively spliced to one of the other 5’ exons upstream, each 
of which respond to different cellular stimuli, allowing different transcripts to be 
generated that are stable in multiple intracellular environments (Pruunsild et al, 2007). It 
is this transcriptional responsiveness which allows BDNF to be secreted and function 
across multiple intra- and extra-cellular domains, primarily in neurons but it is also 
expressed peripherally, such as within endothelial cells and leukocytes (Gass and Hellweg, 
2010).  
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1.7 BDNF is associated with cognitive ageing  
BDNF has been implicated in the ‘age-by-disease hypothesis’, in which BDNF expression is 
reduced in the ageing brain and a reduction in BDNF expression has been associated with 
multiple neurological disorders (McKinney et al, 2015). BDNF is widely regarded for its 
influence on synaptic plasticity, which is essential for cognitive development and memory 
formation (Lu et al, 2014). BDNF is secreted from peripheral cells as well as neurons, 
which brings into question the role of peripheral BDNF in cognition. Notably, BDNF 
actively crosses the blood-brain barrier (BBB) in both directions (Poduslo et al, 1996; Pan 
et al, 1998), meaning peripheral BDNF is from the same reserve as BDNF within the CNS. 
Therefore the consensus is that peripheral BDNF directly influences neuronal and 
cognitive function.  
The genetics of BDNF has also been considered to contribute to the different progression 
of cognitive ageing between individuals. The BDNF Val66Met polymorphism is located 
within the coding strand of the human BDNF gene (Figure 1.5) and is responsible for an 
amino-acid substitution of valine to methionine at codon 66. It has been observed to 
inhibit the activity dependent secretion of BDNF (Chen et al, 2004), and has been 
implicated in cognitive ageing (Miyajima et al, 2008; Lim et al, 2013).  
Reductions in BDNF have been widely investigated as a mediator of age-associated 
decline in synaptic density and cognitive function (Gloriosso et al, 2011), with a significant 
association between BDNF and cognitive ageing being observed (Komulainen et al, 2008; 
Erickson et al, 2010; Oh et al, 2016). However, the underlying mechanisms behind age-
associated BDNF declines were less understood, and so epigenetics was postulated as a 
potential regulator. 
1.8 Epigenetics 
Epigenetics, first defined by Conrad Waddington (1942) as “epi” or above “genetics” to 
bridge the disparity between genotype and phenotype, has emerged from controversial 
origins to become a field that could potentially progress the understanding of a vast 
amount of molecular and cellular processes. 
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Epigenetics can be defined as ‘molecular factors and processes around DNA that are 
mitotically stable and regulate genome activity independent of DNA sequence’ (Skinner et 
al, 2010). 
DNA methylation is by far the most studied epigenetic mechanism, in which DNA 
methyltransferases (DNMTs) transfer a methyl (-CH3) group to the fifth carbon on the six-
atom ring of cytosine, modifying it to 5-methylcytosine (5mC). This process only occurs to 
a cytosine in a CpG (5’-cytosine-phoshphate-guanine-3’) dinucleotide. 5mC is abundant in 
the genome, consisting of ~1% of the total bases, which means almost 80% of human CpG 
dinucleotides are methylated (Ehrlich, 1982). However, potentially the areas of most 
interest are the predominantly unmethylated CpG islands (CGIs), which contain a high 
concentration of CpGs and are associated with the promoter regions of human genes 
(Bird, 2002; Illingworth et al, 2010; Maunakea et al, 2010). Methylated cytosines are 
associated with inhibition of transcription due to the function of the methyl group. They 
can prevent transcription factors from binding to DNA where they are present, and 
recruit methyl-binding proteins (MBPs), which also inhibit transcription factor binding as 
well as forming repressive protein complexes (Klose and Bird, 2006) (Cedar and Bergman, 
2009).  
Histone modifications encompass a vast array of changes that alter the structure of 
chromatin, some of which are displayed in Figure 1.4. One such modification is histone 
acetylation of the global histone domain and the N-terminal tails, which is regulated by 
histone acetyltransferases (HATs) and histone deacetylates (HDACs) (Bannister and 
Kouzarides, 2011). Modifications to lysine 27 of histone H3 (H3K27) have been found at 
BDNF promoters I, II, IV and VI in mature hippocampal neurons (Palomer et al, 2016). 
H3K27 tri- (me3) and di- (me2) methylation is associated with gene silencing, with 
H3K27me3 important in inhibiting transcription and cell stability (Farrari et al, 2013), 
whereas H3K27Ac is found in actively transcribed genes (Tie et al, 2009). 
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1.9 BDNF epigenetics 
Epigenetic mechanisms have been widely shown to regulate BDNF expression, with 
studies predominantly evaluating BDNF promoter methylation. With CGIs near many of 
the promoters of BDNF, including I and IV (Figure 1.5), methylation of the promoters is 
clearly important in regulating the different transcripts generated from their multiple 
cellular sources. BDNF methylation has been highly implicated in numerous neurological 
conditions, including depression, bipolar disorder and schizophrenia (Karpova et al, 2014; 
Zheleznyakova et al, 2016). Furthermore, BDNF methylation at exons I and IV (Figure 1.5) 
have been associated with learning and memory, and as BDNF methylation is dynamic, 
there is growing interest in investigating BDNF methylation in cognitive ageing, mediated 
by the age-associated decline in BDNF expression (Komulainen et al, 2008; McKinney et 
al, 2015).  
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DNA methylation of BDNF in the peripheral cells has been investigated as a biomarker for 
cognitive ageing, with good reason. It has been recently suggested that, even though 
BDNF methylation differs between neurons and peripheral cells (Davies et al, 2012), 
changes in promoter methylation of BDNF in the periphery could mirror changes in the 
brain (Davies et al, 2012; Kundakovic et al, 2015). Furthermore, with BDNF actively 
crossing the BBB, the epigenetic regulation of peripheral BDNF could affect the levels of 
BDNF within the brain. Notably, Chang et al (2014) have previously reported that higher 
BDNF promoter I methylation might be a risk factor for AD. 
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1.10 Overview and Aims 
The regulation of the BDNF gene presents great promise as a biomarker for neuronal and 
cognitive ageing, with the dynamic BDNF methylation been implicated in ageing and risks of AD. 
However, there is limited research on the direct influence of BDNF regulation and the implication 
of cognitive ageing, as well as what role BDNF methylation actually plays in the onset of AD. 
Therefore, the main aims of this thesis are: 
 To develop the understanding of the role of BDNF in cognitive ageing 
 To investigate how the epigenetic and genetic regulation of BDNF contributes to cognitive 
ageing 
 To determine whether lifestyle factors, such as exercise, influenced the impact of short-
term and long-term epigenetic changes on cognitive ageing 
 To analyse the changes in BDNF methylation in relation to AD 
 To determine whether genetic variations within the BDNF gene can influence its 
epigenetic regulation, and whether these interactions are contributing the cognitive 
ageing process 
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2. Methodology 
2.1 Study Populations  
2.1.1 MyoAge 
Recruitment 
The current study utilised samples from the previously performed MyoAge study 
including young (18-30 years) and old (69-81 years) adults, who were required to be 
physically and mentally healthy, who were recruited across Europe (Manchester, UK; 
Paris, France; Leiden, The Netherlands; Tartu, Estonia and Jyväskylä, Finland). 
Recruitment was standardised between all sites involved, using telephone-screening 
interviews and further screening the research centres, the full criteria were described by 
McPhee et al (2013). Characteristics are presented in Table 2.1, sourced from McPhee et 
al (2013). Physically active old adults were defined as having currently maintained 
moderate to vigorous activity for at least 3 years, with at least three 30 minute sessions 
per week, with the intent to improve health and fitness. Inactive old adults were defined 
as having only performed at maximum one session per week to improve health and 
fitness, for the past 3 months, while rarely being active in their daily lives (McPhee et al, 
2013). 
Ethical approval was granted from each institution involved in the cohort, and all 
participants provided written informed consent and were medically screened before 
participation. 
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Table 2.1. MyoAge cohort participant characteristics (n=361) 
 
Young Old 
 
(n=135) (n=226) 
Age (years), Mean (SD) 23.4 (2.74) 74.5 (3.38) 
Females, n (%) 71 (52.6) 116 (51.3) 
MyoAge Institution, n (%)     
Holland 33 (24.4) 71 (31.4) 
Finland 34 (25.2) 68 (30.1) 
Estonia 33 (24.4) 47 (20.8) 
France 17 (12.6) 17 (7.5) 
United Kingdom 18 (13.3) 23 (10.2) 
Education1, n (%)     
Basic School 0 (0) 33 (17.8) 
High School 14 (12.3) 70 (37.8) 
University  100 (87.7) 82 (44.3) 
Mental State     
MMSE Score2, median (IQR) 30 (29-30) 29 (28-30) 
GDS Score3, median (IQR)  0 (0-1) 1 (0-2) 
Activity in old adults     
Active, n (%) - 124 (54.9) 
Inactive, n (%) - 102 (45.1) 
Methylation (%), mean (SD)   
BDNF exon I 4 4.64 (1.32) 5.79 (2.17) 
BDNF exon IV 5 4.65 (1.85) 4.32 (1.32) 
Val66Met genotype6     
Methionine allele present 
(AA/AG), n (%) 
33 (24.4) 76 (33.6) 
1Recorded data in young: n=114, and old: n=185. 2Recorded data in young: n=134, and old: n=223. 
3Recorded data in young: n=116, and old: n=200. 4Recorded data in young: n=62, and the old: n=86. 
5Recorded data in young: n=85, and the old: n=85. 6Recorded data in young: n=127, and old: n=204. 
 
Mental state and cognitive testing 
The Geriatric Depression Scale (Yesavage et al, 1982) was used to screen for depression, 
with those with a score of 5 points or over excluded from the study. The Mini Mental 
State Examination (Folstein et al, 1975) was used to screen for cognitive impairment, 
where a score of 23 points or lower is attributable to factors other than healthy cognitive 
decline, and would exclude the participant from the study. The Cambridge 
Neuropsychological Test Automated Battery (CANTAB) device (Cambridge Cognition Ltd., 
Cambridge, UK) was used to measure various cognitive domains (Sahakian and Owen, 
1992). Participants were given the following tests: 
23 
 
Spatial Span (SSP) is a test of working memory capacity (Owen et al, 1990). Briefly, 
participants were required to observe a series of white squares on the screen in a 
pseudo-random pattern. Some squares would briefly change colour in a randomly 
generated sequence, then a tone would signal the participant to attempt to repeat the 
pattern. A score was given based on the longest sequence successfully recalled by the 
participant. 
One Touch Stockings of Cambridge (OTS) is a test of executive functioning, otherwise 
known as the planning task (Owen et al, 1995). The participants were presented with two 
displays on a screen (Figure 2.1) and they had to work out the minimum number of moves 
required to match the top display to the bottom. A score was given based on the number 
of tasks the participant correctly worked out on their first attempt. 
 
Figure 2.1. One Touch Stockings of Cambridge task. Participants had to work out in their heads the minimum 
number of moves required to match the top display to the bottom. 
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Paired Associates Learning (PAL) is a test of episodic memory (Owen et al, 1993). 
Participants were required to remember the location of specific patterns, which were 
contained within white boxes displayed on the screen. A score is worked out based on the 
number of errors accumulated, when incorrectly guessing which box contained a specific 
pattern. 
2.1.2 Dyne-Steele  
This study utilised samples of the prefrontal cortex donated by participants who had 
undergone a program of longitudinal testing as part of the Dyne-Steele cohort (Rabbitt et 
al, 2004). As part of this program, participants aged from 42 to 92 years, had undergone 
longitudinal cognitive testing across a period of 36 months to 20 years. Participants 
repeatedly filled out self-rating inventories throughout the study, including Yesavage 
depression (Yesavage et al, 1982), personal details and self-awareness questionnaires. 
From the cohort, 67 participants were analysed in this study. Their characteristics are 
displayed in table 2.2, sourced from Payton et al (2015). AD classification was determined 
based on the neuropathology scores following the National Institute on Aging-Alzheimer’s 
Association guidelines (Hyman et al, 2012). Ethical approval was granted by the 
Manchester Brain Bank. 
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Table 2.2. Dyne-Steele cohort participant characteristics (n=67) 
  Control AD Total 
 
(n=17) (n=27) (n=67) 
Age at death (years), Mean (SD) 87.5 (5.35) 87.6 (6.94) 87.5 (6.07) 
Females, n (%) 12 (70.6) 21 (77.8) 46 (68.7) 
Neuropathology group, Mean (SD)       
Thal 0.88 (1.05) 3.63 (1.01) 2.16 (1.71) 
Cerad 0.47 (0.51) 2.41 (0.50) 1.36 (1.07) 
Braak 0.82 (0.39) 2.26 (0.45) 1.56 (0.79) 
Methylation (%)(a), Mean (SD)       
BDNF exon I - - 3.48 (1.18) 
BDNF exon IV - - 2.28 (0.25) 
        
Brain weight (g)(b), Mean (SD) 
- - 
1207.4 
(137.4) 
Cognitive decline (g-factor), Mean (SD)     
Fluid Intelligence 
0.496 
(0.734) 
0.219 (0.699) 0.398 (0.757) 
Vocabulary 
0.647 
(0.787) 
0.488 (0.903) 0.531 (0.776 
Speed 
0.648 
(0.693) 
-0.051 
(0.842) 
0.186 (0.826) 
Memory 
0.429 
(0.726) 
0.536 (1.148) 0.459 (0.936) 
rs56133711 genotype       
Varient allele present (AA/AG), n (%) - - 31 (46.3) 
A) Recorded data: n=66. B) Recorded data: n=43 
 
Cognitive scores for the participants were constructed in a previous study (Payton et al, 
2015). Vocabulary was tested using the Mill Hill and Wais vocabulary tests (Raven, 1965; 
Rabbitt et al, 2004). Tests for fluid intelligence comprised the Alice Heim test 4 (Heim, 
1970) and the Culture Fair Test (Cattell, 1949). Tests for cognitive speed comprised the 
Alphabet Coding Task (Savage, 1984) and the Random Letters test (Rabbitt et al, 2004). 
Memory scores were created based on tests involving Immediate Verbal Free Recall, 
Delayed Recall, spatial memory, semantic memory and prepositions (Rabbitt et al, 2004). 
2.2 Blood extraction 
Whole blood was extracted following an overnight fast and processed, as described in 
McPhee et al (2013). Aliquots of plasma and buff coat samples were requested for this 
current study and stored at -80°C for until further testing. 
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2.3 DNA extraction 
Genomic DNA was extracted from the MyoAge blood samples prior to this study. 
Genomic DNA was extracted from brain samples with the Isolate II Genomic DNA Kit 
(Bioline, UK), according to the manufacturer’s instructions. Briefly, samples were 
incubated with 25 μL of proteinase K enzyme and 200 μL of supplied lysis buffer (Buffer 
G3) at 70°C for 30 mins. Following sample lysis, the lysate was applied onto a spin column 
and centrifuged to allow DNA binding. Subsequent column washes were applied to 
remove unwanted proteins and salts. Finally, the columns were briefly dried and the DNA 
was eluted with 50 μL of pre-warmed elution buffer. 
DNA quantification and purity was performed on the NanoDrop 2000c (Thermo Scientific, 
Wilmington, USA). The 260/280 and 260/230 ratios were used to indicate whether the 
samples were protein and salt free. Stock solutions were then aliquoted and stored at -
20°C until further analysis. 
2.4 Bisulfite treatment 
Genomic DNA samples (10 μL) were bisulfite-converted using the EpiMark® Bisulfite 
Conversion Kit (New England Biolabs® Inc.) according to the protocol. DNA samples were 
combined with the prepared bisulfite mix and incubated in a thermocycler (SureCycler 
8800; Agilent Technologies Inc., Santa Clara, USA), with the specified cycling conditions, 
to deaminate the unmethylated cytosines to uracil (Frommer et al, 1992). Once 
converted, the bisulfite DNA was briefly mixed with DNA Binding Buffer before being 
transferred to the EpiMark spin columns for desulphonation and purification. A final 
volume of 40 μL was stored at -20°C. 
2.5 Primer optomisation 
BDNF promoter primers were designed via the PyroMark Assay Design 2.0 software 
(Qiagen, Hilden, Germany). BDNF primers are presented in table 2.3 and sequences 
analysed are in Figure 2.2. 
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Table 2.3. Human BDNF primers used for bisulfite pyrosequencing 
Primer Sequence (5'-3') 
BDNF exon I Forward TGAGTGATGATTAAATGGGGATTG 
BDNF exon I Forward ACTATTAACTCACATTTAAAAAACCATAAC 
BDNF exon I Forward TGGGGATTGGGGGGA 
  BDNF exon IV Forward GATTTTGGTAATTCGTGTATTAGAGTGTT 
BDNF exon IV Forward AGATTAAATGGAGTTTTCGTTGAT 
BDNF exon IV Forward AATGGAGTTTTCGTTGATGGGGTGCA 
 
 
Figure 2.2. BDNF sequences analysed in bisulfite pyrosequencing. Sequences are in the promoter 
regions of BDNF exon I (Bottom) and BDNF exon IV (Top). Green- CGIs.  
2.6 Polymerase chain reaction (PCR) 
The PCR solutions were prepared as follows, BDNF Ex1: 2 μL bisulfite DNA, 10 μL MyTaq® 
HS mix (Bioline), 1 μL forward primer, 1 μL reverse primer and 6 μL nuclease-free H2O; 
BDNF Ex4: 2 μL bisulfite DNA, 10 μL MyTaq® HS mix (Bioline), 0.5 μL forward primer, 0.5 
μL reverse primer and 7 μL nuclease-free H2O. Total reaction volumes were 20 μL. 
Solutions were prepared on ice and spun down into 96-well plates prior to amplification 
in the thermocycler (Table 2.4; SureCycler 8800; Agilent Technologies Inc., Santa Clara, 
USA). PCR products were stored at -20°C. 
Table 2.4. PCR cycling conditions for BDNF exon I and IV   
Step Description 
Temperature 
(°C) 
Time  Number of cycles per step 
1 Initial Denaturation 95 15 minutes 1 cycle 
2* 
Denaturation 94 30 seconds 
50 cycles* Annealing 56 30 seconds 
Extension 72 45 seconds* 
3 Final Extension 72 10 minutes 1 cycle 
Conditions above for BDNF exon I. *BDNF exon IV was similar apart from 49 cycles and 30 seconds extension at Step 2 
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2.7 Agarose gel electrophoresis 
Gels contained 2% agarose and Midori Green Advance DNA Stain (NIPPON Genetics 
Europe) within 1x tris-borate-EDTA (TBE) buffer. PCR products were mixed with 5x DNA 
loading buffer (Bioline) and were loaded against a 50 bp DNA hyperladder (Bioline). Gels 
were imaged using the Chemedoc® Touch imaging system (Bio-Rad). 
2.8 Bisulfite pyrosequencing 
For epigenetic analysis, DNA methylation and allele discrimination within the BDNF 
promoters was determined using bisulphite pyrosequencing, on the Pyromark Q24 
system (Qiagen, Hilden, Germany). The process, involving the use of PyroMark Q24 
Advanced CpG reagents, was performed in accordance with the manufacturer’s protocol. 
Reagents included a sequencing master mix prepared by mixing Streptavidin Sepharose 
High Performance beads (GE Healthcare Biosciences), Pyromark binding buffer and 
nuclease-free H2O in a ratio of 1:40:24 µL, respectively. This master mix was combined 
with 15 µL of PCR product in a 24-well PCR plate, which was then shaken at 1400 RPM for 
10 minutes on the TS-100 thermos-shaker (BioSan) at room temperature. Immediately 
after agitation, the samples were processed using the PyroMark Q24 workstation. The 
vacuum was applied to the PCR plate for 15 seconds to ensure all the solution had been 
aspirated and that all the beads had been captured on the filter probes. The filter probes 
were subsequently flush with 70% ethanol, denaturation solution and wash buffer for 5, 5 
and 10 seconds respectively. The filter probes were drained and the beads were 
deposited by shaking the probes in the PyroMark Q24 Plate, containing the diluted 
sequencing primer (0.3 µM). The PyroMark Q24 Plate was heated at 80°C for 2 minutes 
(DB-2D, Dri-Block®, Techne) and then allowed to cool to room temperature. The 
PyroMark Q24 Advanced reagents and nucleotides were loaded into the PyroMark Q24 
Cartridge according the PyroMark Q24 Advanced software (assay design). The PyroMark 
Q24 Advanced software (analysis mode) was used to quantify methylation levels and 
grade the quality of analysis at each variable site. 
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2.9 Genotyping 
Genotyping of the MyoAge cohort was performed on the functional polymorphism, 
Val66Met (dbSNP: rs6265), using a commercial genotyping assay (KASPTM, LGC)). 
Genotyping was performed in accordance with the manufacturer’s protocol. Rs6265 
genotyping mix was prepared with DNA (5 ng/µL), 2x KASP Master Mix, KASP Assay 
(primer) mix and water at a ratio of 2, 5, 0.14 and 3 µL respectively. Total reaction 
volumes were 10 µL. Solutions were prepared on ice and spun down into 96-well plates 
prior to amplification in the Stratagene Mx3000P qPCR system (Agilent). The PCR cycle 
conditions are displayed in table 2.5. 
Table 2.5. PCR cycling conditions for KASP genotyping 
Step Description 
Temperature 
(°C) 
Time  
Number of cycles 
per step 
1 Hot-start activation 94 15 minutes 1 cycle 
2 
Denaturation 94 20 seconds 
10 cycles 
Annealing / Elongation 61-55 
60 seconds (drop 
0.6°C per cycle) 
3# 
Denaturation 94 20 seconds 
26 cycles 
Annealing / Elongation 55 60 seconds 
4#* 
Denaturation 94 20 seconds 
3 cycles 
Annealing / Elongation 57 60 seconds 
Based on LGC manual. # After these steps, the plate was cooled to 30°C for 1 minute, in order to read the plate *Step 4 was only 
required as a recovery if clear genotyping clusters were not obtained, it could be repeated until clear clusters were obtained. 
 
2.10 RNA extraction 
Brain tissue (30 mg) was cut on dry ice and stored in sterile 1.5 mL tubes at -80°C. RNA 
extraction was performed in accordance with the manufacturer’s protocol, based on the 
method by Chomczynski and Sacchi, 1987. Prior to extraction, tissue was stored in dry ice 
to minimise RNA degradation, and immediately homogenised in 1 mL TRIsure™ (Bioline, 
UK), pipetting the solution to break down the tissue. After 5 minutes of incubation at 
room temperature, 0.2 mL of chloroform (Thermo Fisher) was added to the solution, 
which was covered and shaken vigorously for 15 seconds, followed by a further 3-minute 
incubation at room temperature, allowing the water to separate from the chloroform. 
The solution was centrifuged at 12,000 g for 15 minutes at 4°C, separating the proteins 
and lipids, DNA and RNA. The RNA was carefully transferred, without disturbing the 
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interphase, to a sterile 1.5 mL tube and mixed with 0.5 mL cold isopropyl alcohol. The 
samples were incubated for 10 minutes at room temperature, to allow precipitation to 
occur, and centrifuged at 12,000 g for 10 minutes at 4°C. The supernatant was carefully 
removed, 1 mL of 75% ethanol was added to wash the remaining pellet by vortex and the 
tubes were centrifuged at 8,000 g for 5 minutes at 4°C. The ethanol wash was repeated 
once more, after which the ethanol was removed by pipetting and air-drying until just the 
pellet remained. The pellet was dissolved in 20 µL of nuclease-free H2O at -80°C. RNA 
concentrations and purity was quantified using the Nanodrop 2000c (Thermo Scientific, 
Wilmington, USA).  
2.11 Reverse transcription 
The Tetro cDNA synthesis kit (Bioline, UK) was used to reverse transcribe the extracted 
RNA samples, according to the manufacturer’s protocol. In each well of a sterile 96-well 
PCR plate, 2 µg total RNA was mixed by pipetting with 1 µL random hexamers, 1 µL 10mM 
dNTP mix, 4 µL 5x RT buffer, 1 µL RiboSafe RNase Inhibitor, 1 µL Tetro reverse 
transcriptase (200 u/µL) and 10 µL DEPC-treated water. Total reaction volume was 20 µL. 
Solutions were spun down and incubated in the thermocycler (SureCycler 8800; Agilent 
Technologies Inc., Santa Clara, USA) at 25°C for 10 minutes, 45°C for 30 minutes and 85°C 
for 5 minutes. Samples were diluted with 80 µL nuclease-free H2O and stored at -20°C. 
2.12 Real-time polymerase reaction (RT-PCR) 
Relative gene expression was analysed with qPCR using SensiFASTTM SYBR® Lo-ROX kit 
(Bioline), in accordance with the manufacturer’s protocol. The cDNA primers were 
designed using the NCBI primer-BLAST software 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/), with the criteria based of the MIQE 
guidelines (Bustin et al, 2009), including primers spanning at least one exon junction and 
a ‘GC clamp’ at the 3’ end of the primers. Primers are presented in table 2.6. 
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Table 2.6. Human BDNF transcript primers used for RT-PCR  
Primer Sequence (5'-3') Primer efficiencies (%) 
BDNF transcript I Forward CAGCATCTGTTGGGGAGACGA 94.7 
BDNF transcript I Reverse GCCACCTTGTCCTCGGATGT  
Accession number NM_170731.4  
Product size 180bp  
  
 
BDNF transcript IV Forward TGGGAGTTTTGGGGCCGAAG 101.7 
BDNF transcript IV Reverse TGGTCATCACTCTTCTCACCTGG  
Accession number NM_170733.3  
Product size 102bp  
  
 
BDNF total Forward GGACCCTTCAGAGGTGGCTC 104.4 
BDNF total Reverse GTCGGCTTGAGTGTGGTCCT  
Product size 123bp  
   
ACTB Forward CATCCTCACCCTGAAGTACC 92.0 
ACTB Reverse ATAGCAACGTACATGGCTGG  
Accession number NM_001101.3  
Product size 219bp  
   
GAPDH Forward CCGCATCTTCTTTTGCGTCG 91.0 
GAPDH Reverse TGGAATTTGCCATGGGTGGA  
Accession number NM_002046.5  
Product size 102bp  
   
 
The PCR solutions were prepared as follows: 2 μL cDNA template, 10 μL SensiFASTTM 
SYBR® Lo-ROX Mix (Bioline), 0.5 μL forward primer, 0.5 μL reverse primer and 7 μL 
nuclease-free H2O; BDNF Ex4: 2 μL bisulfite DNA, 10 μL MyTaq® HS mix (Bioline), 0.5 μL 
forward primer, 0.5 μL reverse primer and 7 μL nuclease-free H2O. Total reaction volumes 
were 20 μL. Solutions were prepared on ice and spun down into 96-well plates prior to 
amplification in the Stratagene Mx3000P qPCR system (Agilent). The PCR cycle conditions 
are displayed in table 2.7.  
Table 2.7. PCR cycling conditions for RT-PCR 
Step Description 
Temperature 
(°C) 
Time  
Number of cycles 
per step 
1 
Polymerase 
activation 
95 2 minutes 1 cycle 
2 
Denaturation 95 5 seconds 
40 cycles Annealing 60* 10 seconds 
Extension 72 10 seconds 
3 Melt-profile analysis 
95 1 minute 
1 cycle 55 30 seconds 
95 1 minute 
*BDNF exon I PCR was performed with an annealing temperature of 62°C 
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Every plate included every analysed sample in duplicate, as well as 2-4 calibration 
samples and 2-4 non-template control samples. The 2-ΔΔCt equation was used to 
determine relative RNA gene expression (Livak and Schmittgen, 2001), normalised to 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and beta-actin (ACTB).  
2.13 Chromatin Immunoprecipitation (ChIP) 
Brain tissue (30 mg) was cut on dry ice and stored in sterile 1.5 mL tubes at -80°C. ChIP 
was performed according to the methodology of Murgatroyd et al (2012), with revisions 
listed below.  
The chromatin was sheared using the M220 Focused-ultrasonicator (Covaris), to target a 
DNA fragment range of 300-1000 bp with the following settings: water bath temperature- 
6°C, processing time- 8 minutes, duty cycle- 5%, peak incident power- 75 watts, and 
cycles per burst- 200. The remaining debris was pelleted by centrifuging at 10,000 g for 10 
minutes at 4°C, and the supernatant with the sheared protein-DNA complex was 
transferred to new tubes and stored at -80°C. 
For immunoprecipitation, 5 μL supernatant was stored for an input control. Rabbit IgG 
antibody (1 μL) was used for the negative control, while the anti-Histone H3K27ac 
antibody (Abcam, ab4729; 5 μL) was used for the pull-down samples. 
Immune complexes were mixed at 65°C for 30 minutes, and then the beads were 
captured on the magnetic rack, where the supernatant was transferred to a new tube. At 
this point, the input control was diluted with 95 μL elution buffer (to 100 μL). To reverse 
the formaldehyde cross-linking, NaCl (5M, 6 μL) was added to all the tubes and the 
complexes were incubated at 65°C for 4 hours. This was followed by the addition of 
Proteinase K (2.5 μL, 20 mg/ml, Bioline) and incubation at 65°C for 2 hours to degrade any 
remaining bound protein. 
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2.14 Statistical analysis 
The IBM SPSS Statistics software (v.22) was used to analyse all associations. Normal 
distribution of data was determined using the Sharipo-Wilk test for normality. 
Significance was determined by P<0.05.  
Differences in plasma BDNF between different levels of educational attainment were 
determined using Kruskal-Wallis H tests. All other differences in plasma BDNF levels 
between categorical variables were determined using Mann-Whitney U tests. 
Relationships with plasma BDNF and ranked variables were determined using Spearman 
correlations, with Spearman partial correlations used when controlling for age as 
described in the results. 
Cognitive function Z-scores were created against the average of the young populations, 
stratified by gender. Differences in cognitive function between different levels of 
educational attainment were determined using Kruskal-Wallis H tests. Differences in 
cognitive function between the Val66Met genotype while controlling for age were 
determined using an ANCOVA. All other differences in cognitive function between 
categorical variables were determined using Mann-Whitney U tests. Relationships with 
cognitive function and ranked variables were determined using Spearman correlations, 
with Spearman partial correlations used when controlling for age as described in the 
results. 
Differences in BDNF methylation levels between different levels of educational 
attainment were determined using Kruskal-Wallis H tests. All other differences in BDNF 
methylation levels between categorical variables were determined using Mann-Whitney 
U tests. Relationships with BDNF methylation levels and ranked variables were 
determined using Spearman correlations, with Spearman partial correlations used when 
controlling for age as described in the results. 
Differences in total BDNF expression between neuropathology scores and the rs56133711 
genotype were determined using Kruskal-Wallis H tests, with Tukey HSD multiple 
comparisons performed for post-hoc analysis. All other differences in total BDNF 
expression between categorical variables were determined using Mann-Whitney U tests. 
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Relationships with total BDNF expression and ranked variables were determined using 
Spearman correlations, with Spearman partial correlations used when controlling for age 
and neuropathology as described in the results. Differences in BDNF exons I and IV 
expression between neuropathology scores and the rs56133711 genotype were 
determined using one-way ANOVAs, with multiple Mann-Whitney U tests with Bonferroni 
adjustments performed for post-hoc analysis. All other differences in BDNF exons I and IV 
expression between categorical variables were determined using independent samples t-
tests. Relationships with BDNF exons I and IV expression and continuous variables were 
determined using Pearson correlations, with Pearson partial correlations used when 
controlling for age and neuropathology as described in the results. 
Relationships with cross-sectional and longitudinal vocabulary score and ranked variables 
were determined using Spearman correlations, with Spearman partial correlations used 
when controlling for age and neuropathology as described in the results. Relationships 
between all other Dyne-Steele cognitive scores and continuous variables were 
determined using Pearson correlations, with Pearson partial correlations used when 
controlling for age and neuropathology as described in the results. 
Relationships with all individual CpG methylation levels and ranked variables were 
determined using Spearman correlations, with Spearman partial correlations used when 
controlling for age and neuropathology as described in the results. Relationships with 
BDNF average methylation and continuous variables were determined using Pearson 
correlations, with Pearson partial correlations used when controlling for age and 
neuropathology as described in the results. 
BDNF rs56133711 allelic discrimination was determined using a paired-samples T-test. 
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3. Results  
3.1 Association of age and gender on BDNF plasma levels  
A prior analysis of the sets of BDNF values attained from across the different MyoAge 
institutions, showed that the BDNF levels from the Estonian institute were almost 5-fold 
higher than the other institutions (figure 3.1, P<0.0001). Therefore, further analyses 
within this study omitted the Estonian measurements.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BDNF protein levels, previously measured in the plasma extracts, were tested between 
the young and the old populations within the MyoAge cohort. Notably, BDNF levels were 
significantly higher in the older population (P=0.003). When the population was stratified 
by gender (figure 3.2), the significant increase in BDNF levels was attributed to the male 
population (young: 1010.99 pg/mL, old: 2417.72 pg/mL, P<0.001), while no significant 
change was found within the female population (young: 1946.58 pg/mL, old: 2216.77, 
P=0.347). BDNF levels were also significantly higher in the young females than in the 
young males (male: 1010.99 pg/mL, female: 1946.58 pg/mL, P=0.034). 
  
Figure 3.1 Analysis of BDNF plasma protein taken from the MyoAge institutions. 
BDNF protein levels taken from the Estonian institute were almost three standard deviations 
from the mean of the other MyoAge institutions, *P<0.0001 
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3.2 The relationship between plasma BDNF and cognitive function 
The relationship between cognitive performance and age within the MyoAge cohort has 
been described previously (Bradburn et al, 2016), indicating that the older population 
performed worse on the tests of working memory, episodic memory, executive 
functioning and the combined global cognition. 
BDNF levels from the males and females were analysed against the results from the 
cognitive tests (working memory, episodic memory, executive functioning and the 
combined global cognition) using Spearman partial correlation while controlling for age, 
the results are displayed in Table 3.1. No significant correlations were found with BDNF 
across the tests (Figure 3.3).  
Table 3.1 Relationship between BDNF plasma protein and cognitive functioning (stratified by 
gender) 
 
Male Female 
 
BDNF plasma level (Z-Score) BDNF plasma level (Z-Score) 
 
r P r P 
Working memory capacity -0.052 0.560 -0.048 0.572 
Executive functioning -0.001 0.992 -0.119 0.156 
Episodic memory 0.058 0.506 -0.109 0.194 
Global cognition 0.022 0.804 -0.142 0.090 
MMSE 0.033 0.706 0.132 0.117 
r= Spearman correlation coefficient. P= significance 
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Figure 3.2. Analysis of BDNF plasma protein between the young and old adults, 
stratified by gender. Data is presented as mean and standard deviation. * P<0.001. 
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When BDNF levels from the males and females of the older group were analysed against 
the cognitive tests, it was found that there was a significant positive association between 
MMSE scores and plasma BDNF levels in the old females (Table 3.2). 
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Figure 3.3. Relationship between BDNF plasma protein and cognitive function. A) Relationship between 
BDNF plasma protein and episodic memory. B) Relationship between BDNF plasma protein and working memory 
capacity. C) Relationship between BDNF plasma protein and executive functioning. D) Relationship between BDNF 
plasma protein and global cognition. No significant correlations were found. 
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MMSE scores are predictive of cognitive function in the MyoAge cohort and importantly 
in the old females (Table 3.3). This suggests that levels of plasma BDNF may predict 
cognitive performance in older females.  
Table 3.3 Relationship between MMSE scores and cognitive 
functioning in old females 
  Old female adults 
 
MMSE score 
  r P 
Working memory capacity 0.156 0.098 
Executive functioning 0.166 0.080 
Episodic memory  0.173 0.066 
Global cognition 0.190 0.044 
r= Spearman correlation coefficient. P= significance 
 
  
Table 3.2 Relationship between BDNF plasma protein and cognitive functioning (stratified 
by age and gender) 
  Male Female 
 
BDNF plasma level (Z-
Score) 
BDNF plasma level (Z-
Score) 
  r P r P 
Young         
Working memory capacity -0.182 0.207 -0.247 0.077 
Executive functioning -0.149 0.301 -0.145 0.305 
Episodic memory  0.062 0.667 -0.176 0.212 
Global cognition -0.151 0.294 -0.262 0.061 
MMSE -0.205 0.153 -0.062 0.663 
Old         
Working memory capacity 0.097 0.374 0.003 0.977 
Executive functioning -0.010 0.930 0.081 0.445 
Episodic memory  0.062 0.572 -0.067 0.528 
Global cognition 0.093 0.393 -0.046 0.666 
MMSE 0.083 0.446 0.234 0.025 
r= Spearman correlation coefficient. P= significance 
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3.3 Correlation between methylation at individual CPG sites within promoters I 
and IV of the BDNF gene in the blood 
Following the finding that BDNF protein levels may correlate with cognition, we 
investigated the possibility that BDNF gene regulatory potential might differ. In this 
regard, we studied epigenetic marking of the BDNF gene, specifically DNA methylation. 
The BDNF gene has multiple promoters linked to different untranslated first exons. We 
focused our attention on the promoters linked to the alternative first exons I and IV 
(Figure 1.3, introduction). 
Within the promoters of exons I and IV we analysed 5 and 9 CpG sites, respectively. In the 
region analysed within the BDNF exon I promoter, the methylation of all the CpG sites 
were significantly correlated with one another (Figure 3.4 left, r>0.490, p<0.001). This was 
also the case with the BDNF exon IV promoter region (Figure 3.4 right, r>0.290, p<0.001). 
Therefore, an average methylation score could be made for both regions. 
 
Figure 3.4. Spearman’s correlation between CpGs in BDNF exon I (left) and IV (right). All correlations were 
significant (p<0.001) 
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3.4 Relationship between BDNF methylation in the blood and age 
Methylation in the promotor region of BDNF exon I was significantly higher in the older 
population in four out of the five CpG sites and across the average of the location. No 
significant changes were seen in any of the CpG sites in the promoter region of exon IV 
(Table 3.4, Figure 3.5).  
Table 3.4 Relationship between BDNF methylation and age 
  
  
Young adults Old adults 
 
  
n Methylation (Z-Score) n Methylation (Z-Score) P 
BDNF Exon I 
      
 
CpG 1 59 2.99 (0.00) 86 3.48 (0.20) 0.664 
 
CpG 2 59 5.27 (0.00) 86 6.46 (0.58) 0.011 
 
CpG 3 59 5.72 (0.00) 86 7.29 (0.71) <0.001 
 
CpG 4 59 4.1 (0.00) 86 5.23 (0.79) 0.001 
 
CpG 5 59 5.11 (0.00) 86 6.47 (0.65) 0.001 
 
Average 59 4.64 (0.00) 86 5.79 (0.96) <0.001 
BDNF Exon IV 
      
 
CpG 1 68 4.99 (0.00) 74 4.85 (-0.04) 0.910 
 
CpG 2 68 3.11 (0.00) 74 2.76 (-0.06) 0.603 
 
CpG 3 68 3.84 (0.00) 74 3.41 (-0.14) 0.235 
 
CpG 4 68 6.53 (0.00) 74 5.67 (-0.30) 0.076 
 
CpG 5 68 3.79 (0.00) 74 3.22 (-0.21) 0.228 
 
CpG 6 68 2.66 (0.00) 74 2.88 (-0.02) 0.804 
 
CpG 7 68 6.29 (0.00) 74 5.54 (-0.20) 0.115 
 
CpG 8 68 4.05 (0.00) 74 3.78 (-0.24) 0.079 
 
CpG 9 68 6.64 (0.00) 74 6.80 (-0.10) 0.515 
 
Average 68 4.65 (0.00) 74 4.32 (-0.19) 0.324 
BDNF methylation is presented as a percentage, with Z-Scores based of the average of the young male and female 
populations separately. P values were determined by independent samples Mann-Whitney U tests 
 
 
 
 
 
 
 
 
 
 
B D N F  E x 1  C p G
M
e
th
y
la
ti
o
n
 (
Z
-S
c
o
r
e
)
C
p
G
 1
C
p
G
 2
C
p
G
 3
C
p
G
 4
C
p
G
 5
A
v
e
ra
g
e
-5
0
5
1 0
Y o u n g
O ld
B D N F  E x 4  C p G
M
e
th
y
la
ti
o
n
 (
Z
-S
c
o
r
e
)
C
p
G
 1
C
p
G
 2
C
p
G
 3
C
p
G
 4
C
p
G
 5
C
p
G
 6
C
p
G
 7
C
p
G
 8
C
p
G
 9
A
v
e
ra
g
e
-1 0
-5
0
5
Y o u n g
O ld
Figure 3.5. Relationship between BDNF methylation and age. A) Relationship between BDNF exon I 
methylation and age, old adults had significantly higher BDNF exon I methylation than the young adults (Average: 
P<0.001) B) Relationship between BDNF exon IV methylation and age, no significant differences were observed. 
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The differences in BDNF methylation in exon I between age groups were then analysed 
within the male and female populations, separately (Table 3.5, Figure 3.6). Notably, the 
vast majority of the significant increase in BDNF methylation in the older population was 
attributed to the female population. Within the female population, four out of the five 
CpG sites had significantly higher methylation levels. In the male population, methylation 
had also increased with age, with a significant increase at CpG 3 and smaller trends across 
the other sites. 
Table 3.5 Relationship between BDNF exon I methylation and age, stratified by gender 
  
Male 
P value 
Female 
P value 
  
Methylation (Z-Score) Methylation (Z-Score) 
  
Young Old Young Old 
BDNF Exon I 
       
 
CpG 1 3.15 (0.00) 3.42 (0.09) 0.909 2.87 (0.00) 3.53 (0.29) 0.527 
 
CpG 2 5.48 (0.00) 6.08 (0.18) 0.381 5.10 (0.00) 6.78 (0.90) 0.006 
 
CpG 3 5.89 (0.00) 7.01 (0.53) 0.031 5.59 (0.00) 7.52 (0.87) 0.001 
 
CpG 4 4.24 (0.00) 5.15 (0.50) 0.073 4.00 (0.00) 5.30 (1.03) 0.002 
 
CpG 5 5.52 (0.00) 5.97 (0.24) 0.304 4.80 (0.00) 6.87 (0.98) 0.001 
 
Average 4.86 (0.00) 5.53 (0.44) 0.068 4.47 (0.00) 6.00 (1.39) 0.001 
BDNF methylation is presented as a percentage, with Z-Scores based of the average of the young male and female 
populations separately. P values were determined by independent samples Mann-Whitney U tests 
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Figure 3.6. Relationship between BDNF exon I methylation and age, in males and females.                             
A) Young and old males, old males had marginally higher BDNF exon I methylation than the young males 
(Average: P=0.068) B) Young and old females, old females had significantly higher BDNF exon I methylation 
than the young females (Average: P=0.001). 
A B 
42 
 
3.5 Relationship between BDNF methylation and BDNF protein levels in the plasma 
To determine whether BDNF methylation was influencing BDNF protein levels within the 
plasma, Spearman’s correlations were performed between the methylation scores of 
BDNF exon I and IV, and BDNF protein levels, while controlling for age. No significant 
relationships were found between BDNF methylation and BDNF protein levels (Table 3.6, 
Figure 3.7). 
Table 3.6 Relationship between BDNF methylation and BDNF plasma protein, 
stratified by gender 
  
Male 
 
Female 
  
BDNF plasma level (Z-
Score) 
 
BDNF plasma level (Z-
Score) 
  
r P 
 
r P 
BDNF Exon I 
      
 
CpG 1 -0.030 0.826 
 
-0.163 0.195 
 
CpG 2 0.021 0.881 
 
-0.108 0.388 
 
CpG 3 0.064 0.636 
 
-0.136 0.277 
 
CpG 4 -0.086 0.524 
 
-0.088 0.480 
 
CpG 5 0.058 0.671 
 
-0.026 0.838 
 
Average -0.018 0.892 
 
-0.091 0.466 
BDNF Exon 
IV       
 
CpG 1 0.043 0.744 
 
0.068 0.557 
 
CpG 2 0.062 0.642 
 
-0.114 0.348 
 
CpG 3 -0.087 0.514 
 
-0.016 0.890 
 
CpG 4 0.022 0.868 
 
0.053 0.647 
 
CpG 5 0.092 0.494 
 
-0.006 0.957 
 
CpG 6 0.033 0.819 
 
0.042 0.729 
 
CpG 7 0.011 0.934 
 
0.091 0.436 
 
CpG 8 0.015 0.910 
 
0.143 0.225 
 
CpG 9 -0.039 0.771 
 
0.140 0.233 
 
Average -0.032 0.807 
 
0.095 0.416 
r= Spearman correlation coefficient 
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Figure 3.7. Relationship between BDNF methylation and plasma BDNF Left) Relationship between 
BDNF exon I methylation and plasma BDNF. Right) Relationship between BDNF exon IV methylation 
and plasma BDNF. No significant associations were observed. 
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With the previous observation that plasma BDNF was positively associated with MMSE 
scores within the old females, the population was further stratified by age, in order to 
determine whether accumulated BDNF methylation had a specific effect on plasma BDNF 
in later life. Further analysis showed that there were no significant associations between 
BDNF methylation and plasma BDNF levels in the old male or old female populations 
(Table 3.7), meaning methylation at these specific regions was not contributing to the 
differences in plasma BDNF in the old females, that was associated with improved 
cognitive function. 
 
 
  
Table 3.7 Relationship between BDNF methylation and BDNF plasma protein (stratified by age 
and gender) 
    Young male Old male Young female Old female 
  
BDNF plasma 
level (Z-Score) 
BDNF plasma 
level (Z-Score) 
BDNF plasma 
level (Z-Score) 
BDNF plasma 
level (Z-Score) 
    r P r P r P r P 
BDNF Exon I 
         
 
CpG 1 0.139 0.536 -0.131 0.453 -0.251 0.227 -0.122 0.454 
 
CpG 2 0.046 0.842 -0.037 0.833 -0.061 0.766 -0.073 0.655 
 
CpG 3 0.095 0.675 -0.057 0.744 -0.115 0.576 -0.093 0.566 
 
CpG 4 -0.034 0.880 -0.206 0.235 -0.106 0.605 -0.036 0.826 
 
CpG 5 -0.140 0.533 0.100 0.566 -0.071 0.732 0.064 0.697 
 
Average 0.078 0.730 -0.132 0.450 -0.038 0.855 -0.051 0.757 
BDNF Exon 
IV          
 
CpG 1 0.139 0.481 -0.188 0.295 0.017 0.919 0.110 0.504 
 
CpG 2 0.562 0.002 -0.441 0.012 -0.236 0.179 0.006 0.973 
 
CpG 3 -0.042 0.833 -0.147 0.431 -0.054 0.756 0.024 0.887 
 
CpG 4 0.225 0.249 -0.147 0.429 -0.089 0.600 0.132 0.425 
 
CpG 5 0.427 0.026 -0.251 0.174 0.013 0.939 -0.016 0.925 
 
CpG 6 0.103 0.640 -0.144 0.456 -0.006 0.975 0.044 0.798 
 
CpG 7 0.095 0.639 -0.041 0.812 0.001 0.997 0.112 0.496 
 
CpG 8 0.139 0.481 -0.074 0.687 0.097 0.579 0.150 0.361 
 
CpG 9 -0.095 0.636 -0.045 0.806 0.005 0.976 0.243 0.136 
  Average 0.030 0.881 -0.172 0.338 0.012 0.945 0.164 0.318 
r= Spearman correlation coefficient 
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3.6 Relationship between BDNF methylation in the blood and cognition 
Though there was no significant relationship between BDNF methylation and peripheral 
BDNF protein levels, we investigated whether BDNF methylation may still function as a 
marker for cognitive differences. Spearman partial correlations were performed between 
BDNF exon I and IV methylation, and the tests of cognitive function, while controlling for 
age. Methylation of BDNF exon I was negatively associated with executive functioning 
scores, however no significant associations were found with BDNF exon IV (Table 3.8, 
Figure 3.8). 
 
Table 3.8 Relationship between BDNF methylation and cognitive function 
  
Executive 
Functioning 
Working memory 
capacity Episodic Memory Global Cognition 
  
  
r P r P r P r P 
BDNF 
exon I 
         
 
CpG 1 -0.089 0.290 0.024 0.771 -0.016 0.850 -0.018 0.829 
 
CpG 2 -0.232 0.005 -0.050 0.550 -0.042 0.620 -0.116 0.166 
 
CpG 3 -0.205 0.014 -0.098 0.244 -0.041 0.624 -0.133 0.112 
 
CpG 4 -0.216 0.009 -0.060 0.472 -0.098 0.243 -0.144 0.085 
 
CpG 5 -0.239 0.004 -0.108 0.197 -0.072 0.391 -0.178 0.033 
 
Average -0.218 0.009 -0.075 0.370 -0.057 0.497 -0.133 0.112 
BDNF 
exon IV 
         
 
CpG 1 -0.088 0.301 -0.043 0.616 0.013 0.878 -0.079 0.352 
 
CpG 2 -0.089 0.294 -0.067 0.428 -0.026 0.764 -0.089 0.297 
 
CpG 3 0.014 0.865 0.009 0.915 0.037 0.664 0.037 0.661 
 
CpG 4 -0.015 0.858 0.023 0.789 0.016 0.847 -0.005 0.950 
 
CpG 5 -0.067 0.428 0.050 0.557 -0.072 0.395 -0.073 0.393 
 
CpG 6 -0.112 0.188 0.030 0.726 -0.042 0.625 -0.080 0.343 
 
CpG 7 -0.073 0.387 0.023 0.789 0.001 0.987 -0.058 0.493 
 
CpG 8 -0.116 0.170 -0.013 0.876 -0.022 0.792 -0.068 0.421 
 
CpG 9 -0.042 0.620 -0.047 0.580 -0.129 0.126 -0.091 0.284 
 
Average -0.071 0.401 -0.005 0.957 -0.046 0.590 -0.081 0.339 
r= Spearman's correlation coefficient 
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When the population was stratified by gender, the negative association previously 
displayed between BDNF exon I methylation and executive functioning was attributed to 
the Male population, with further negative trends displayed between BDNF exon I and 
working memory capacity and global cognition scores (Table 3.9). 
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Figure 3.8. Relationship between BDNF methylation and cognitive function Top) Relationship 
between BDNF exons I and IV methylation and global cognition. Bottom) Relationship between BDNF 
exons I IV methylation and executive functioning. BDNF exon I was significantly associated with 
executive function (P=0.009) 
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Table 3.9 Relationship between BDNF exon I methylation and cognition, stratified by 
gender 
  Executive 
functioning 
Working 
memory 
capacity 
Episodic 
memory Global cognition 
      r P r P r P r P 
Male 
         
 
CpG 1 -0.210 0.096 -0.157 0.216 -0.197 0.119 -0.153 0.227 
 
CpG 2 -0.347 0.005 -0.134 0.291 -0.044 0.727 -0.163 0.199 
 
CpG 3 -0.470 <.001 -0.237 0.060 -0.065 0.608 -0.283 0.023 
 
CpG 4 -0.407 0.001 -0.216 0.086 -0.111 0.381 -0.219 0.082 
 
CpG 5 -0.363 0.003 -0.141 0.265 -0.029 0.819 -0.170 0.180 
 
Average -0.467 <.001 -0.255 0.042 -0.083 0.516 -0.256 0.041 
Female 
         
 
CpG 1 0.035 0.759 0.240 0.033 0.075 0.513 0.126 0.269 
 
CpG 2 -0.159 0.163 0.072 0.530 -0.102 0.371 -0.108 0.341 
 
CpG 3 0.003 0.982 0.066 0.564 -0.096 0.402 -0.021 0.856 
 
CpG 4 -0.088 -0.088 0.089 0.437 -0.081 0.478 -0.055 0.631 
 
CpG 5 -0.154 0.175 0.001 0.997 -0.173 0.127 -0.163 0.150 
  Average -0.070 0.538 0.102 0.373 -0.083 0.469 -0.041 0.722 
r= Spearman's correlaton coefficient 
It was found that when the male population was stratified by age, there was still a strongly 
significant negative association between BDNF exon I methylation and executive functioning 
in the old males (Table 3.10), as well as a significant negative association between BDNF exon 
I methylation and working memory capacity. This suggests that BDNF exon I methylation 
could predict certain aspects of cognitive function in old male adults. 
Table 3.10 Relationship between BDNF exon I methylation and cognition in males, stratified by age 
    Male 
  Executive 
functioning 
 
Working 
memory 
capacity 
 Episodic 
memory 
 Global 
cognition 
     
  
r P 
 
r P 
 
r P 
 
r P 
Young 
            
 
CpG 1 -0.312 0.113 
 
-0.082 0.683 
 
-0.322 0.102 
 
-0.363 0.062 
 
CpG 2 -0.211 0.300 
 
0.275 0.173 
 
-0.159 0.439 
 
0.065 0.754 
 
CpG 3 -0.259 0.192 
 
0.252 0.205 
 
-0.088 0.663 
 
0.011 0.957 
 
CpG 4 -0.165 0.410 
 
0.241 0.225 
 
-0.356 0.069 
 
0.017 0.933 
 
CpG 5 -0.153 0.445 
 
0.173 0.390 
 
0.008 0.970 
 
0.038 0.849 
 
Average -0.299 0.130 
 
0.210 0.294 
 
-0.245 0.217 
 
-0.068 0.735 
Old 
            
 
CpG 1 -0.346 0.031 
 
-0.282 0.082 
 
-0.110 0.507 
 
-0.193 0.238 
 
CpG 2 -0.415 0.009 
 
-0.278 0.087 
 
0.059 0.759 
 
-0.170 0.300 
 
CpG 3 -0.570 <0.001 
 
-0.438 0.005 
 
-0.054 0.745 
 
-0.333 0.038 
 
CpG 4 -0.446 0.004 
 
-0.300 0.063 
 
0.024 0.887 
 
-0.171 0.297 
 
CpG 5 -0.464 0.003 
 
-0.327 0.042 
 
-0.005 0.977 
 
-0.220 0.179 
 
Average -0.524 0.001 
 
-0.403 0.011 
 
0.006 0.973 
 
-0.237 0.147 
r= Spearman correlation coefficient 
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3.7 Relationship between cognition and physical activity in the old adults 
Cognitive function and ageing is not an independent process from the rest of the human 
biological systems, one of the many reasons peripheral BDNF is being analysed within this 
study. However, it also requires the consideration of other factors that could be 
impacting this cognitive ageing, either via independent pathways or through the 
mediation of BDNF. 
When this study analysed the effect of exercise on cognitive function in the old adults, no 
significant differences were presented (Table 3.11). 
 
Table 3.11 Relationship between cognitive function and activity in the older population 
  Active Inactive   
  n Z-Score n Z-Score P 
      Executive functioning 124 -2.709 102 -2.847 0.529 
Working memory capacity 124 -1.897 102 -1.963 0.387 
Episodic memory 124 -3.242 102 -3.648 0.713 
Global cognition 124 -7.848 102 -8.458 0.353 
Cognitive function tests are presented as Z-Scores, based on the average of the young male and female populations 
separately. P values were determined by independent samples Mann-Whitney U tests 
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3.8 Relationship between plasma BDNF and physical activity in the old adults 
While the definitions of physically active and less active in the MyoAge population were 
well defined (McPhee et al, 2013), most of the participants self-assessed their physical 
activity levels, meaning some participants performing a similar amount of physical activity 
may have reported themselves differently. It is currently not known whether there is a 
minimum threshold for exercise to induce neurological changes, and so we do not know 
whether the two groups were significantly different to place either side of such a 
threshold. More likely it is a scaled change, therefore we still analysed BDNF against 
physical activity to see if the exercise was producing changes that could prelude an 
improvement in cognitive function. BDNF protein levels were investigated between the 
active and inactive populations of the old adults, although no significant change was 
observed (Figure 3.9, P=0.138).  
 
 
 
 
 
 
 
 
 
 
 
3.9 Relationship between BDNF methylation in the blood and physical activity in 
the old adults 
Though no significant difference was observed between BDNF protein levels and activity 
in the old adults, we next analysed the BDNF methylation levels between the old active 
and old inactive populations (Table 3.12). No significant differences were found across 
the BDNF exon I region. However, the old active population had reduced methylation 
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Figure 3.9. Relationship between Plasma BDNF and exercise. No 
significant difference was observed between the old active and old 
inactive populations. 
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across the BDNF exon IV region, at CpGs 1, 2, 5, 6, 7, 8 as well as with the average (Figure 
3.10, P<0.01). 
Table 3.12 Relationship between BDNF methylation and activity in the old adults 
  
Active Inactive 
 
  
n Methylation (Z-Score) n Methylation (Z-Score) P 
BDNF Exon I 
      
 
CpG 1 44 3.33 (0.072) 42 3.64 (0.330) 0.315 
 
CpG 2 44 6.18 (0.410) 42 6.75 (0.748) 0.099 
 
CpG 3 44 7.16 (0.666) 42 7.43 (0.766) 0.467 
 
CpG 4 44 5.23 (0.752) 42 5.24 (0.823) 0.521 
 
CpG 5 44 6.26 (0.567) 42 6.68 (0.729) 0.305 
 
Average 44 5.63 (0.859) 42 5.95 (1.058) 0.346 
BDNF Exon 
IV 
      
 
CpG 1 42 4.33 (-0.352) 43 5.35 (0.269) 0.005 
 
CpG 2 40 2.45 (-0.256) 41 3.07 (0.095) 0.013 
 
CpG 3 42 3.38 (-0.224) 39 3.44 (0.061) 0.138 
 
CpG 4 42 5.50 (-0.512) 41 5.84 (0.068) 0.065 
 
CpG 5 41 2.86 (-0.557) 41 3.58 (0.179) 0.001 
 
CpG 6 40 2.71 (-0.208) 39 3.05 (0.202) 0.033 
 
CpG 7 42 5.10 (-0.425) 42 5.98 (0.079) 0.012 
 
CpG 8 42 3.52 (-0.498) 42 4.02 (0.064) 0.024 
 
CpG 9 42 6.71 (-0.169) 41 6.88 (0.044) 0.180 
 
Average 42 4.06 (-0.319) 43 4.58 (0.257) 0.010 
BDNF methylation is presented as a percentage, with Z-Scores based of the average of the young male and female 
populations separately. P values were determined by independent samples Mann-Whitney U tests 
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Figure 3.10. Relationship between BDNF methylation and activity. Left) Relationship between 
BDNF exon I methylation and activity, no significant differences were observed. Right) 
Relationship between BDNF exon IV methylation and activity, the old active group had 
significantly reduced BDNF exon IV methylation (Average: P<0.010). 
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When the population was further stratified by gender (Table 3.13), the difference 
between BDNF exon IV methylation and activity was maintained within the female 
population, with the average methylation of the sites significantly lower in the active 
population in comparison to the inactive (Figure 3.11). The same trend was still observed 
in the male population, however only one CpG site maintained a significant difference. 
Interestingly, the female population also displayed a reduction in BDNF exon I 
meth
ylatio
n, 
with a 
trend 
showi
ng 
across 
the 
regio
n 
(Aver
age- 
P=0.0
73). 
 
 
 
  
Table 3.13 Relationship between BDNF methylation and activity on the old adults, 
stratified by gender 
  
Male 
 
Female 
 
  
Active Inactive P Active Inactive P 
BDNF Exon I n 16 23 
 
28 19 
 
 
CpG 1 0.159 0.040 0.779 0.022 0.681 0.067 
 
CpG 2 0.094 0.245 0.302 0.591 1.357 0.084 
 
CpG 3 0.509 0.548 0.806 0.756 1.030 0.260 
 
CpG 4 0.702 0.356 0.806 0.781 1.388 0.151 
 
CpG 5 0.228 0.256 0.942 0.761 1.301 0.052 
 
Average 0.466 0.414 0.841 1.083 1.837 0.073 
BDNF Exon 
IV 
n 14 19 
 
25 16 
 
 
CpG 1 -0.144 0.381 0.129 -0.468 0.136 0.056 
 
CpG 2 0.396 0.296 0.719 -0.621 -0.143 0.009 
 
CpG 3 0.103 0.180 0.972 -0.408 -0.080 0.057 
 
CpG 4 -0.279 0.404 0.245 -0.643 -0.331 0.249 
 
CpG 5 -3.410 0.475 0.035 -0.678 -0.172 0.028 
 
CpG 6 0.237 0.400 0.522 -0.458 -0.034 0.043 
 
CpG 7 -0.172 0.357 0.102 -0.566 -0.250 0.067 
 
CpG 8 -0.411 0.316 0.075 -0.547 -0.235 0.255 
 
CpG 9 0.030 0.260 0.545 -0.279 -0.212 0.596 
 
Average 0.099 0.591 0.216 -0.553 -0.140 0.033 
BDNF methylation is presented as Z-Scores, based on the average of the young male and female populations separately. 
P values were determined by independent samples Mann-Whitney U tests 
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3.10 Relationship between education and cognitive function, in the old adults 
Education is an environmental factor that contributes to cognitive reserve, with further 
education producing long-term cognitive benefits and protection against 
neurodegeneration. 
In the MyoAge cohort, old adults performed significantly better in all the tests of 
cognition, the further they had progressed their education (Table 3.14).  
Table 3.14 Relationship between education and cognitive function, in the old adults 
 
Basic School High School University 
 
 
n Z-Score n Z-Score n Z-Score P 
Executive functioning 33 -3.055 70 -2.737 82 -2.173 0.030 
Working memory capacity 33 -2.173 70 -1.947 82 -1.727 0.014 
Episodic memory 33 -4.866 70 -2.241 82 -2.664 0.003 
Global cognition 33 -10.094 70 -6.925 82 -6.502 0.008 
P values were determined by independent samples Kruskal-Wallis H tests 
 
Notably, this improvement in cognitive function with further education was only 
attributed to the female population (Table 3.15). No significant differences were 
observed within the old male population. However, there was a trend of better 
performance with University education against basic education in the males (Mann 
Whitney U: Executive functioning- P=0.086, Episodic memory- P=0.097, Global cognition- 
P=0.054). 
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Figure 3.11. Relationship between BDNF methylation and activity, in the female population. Left) Relationship 
between BDNF exon I methylation and activity, in the female population, there was significantly higher methylation in 
the old inactive population (P=0.033). Right) Relationship between BDNF exon IV methylation and activity, in the 
female population, there was marginally higher methylation in the old inactive population (P=0.073). 
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Table 3.15 Relationship between education and cognitive function in the old adults, stratified by 
gender 
  
Basic School High School University 
 
  
n Z-Score n Z-Score n Z-Score P 
Male 
        
 
Executive functioning 14 -3.123 23 -2.270 49 -2.084 0.226 
 
Working memory capacity 14 -1.793 23 -1.718 49 -1.767 0.993 
 
Episodic memory 14 -4.483 23 -1.878 49 -2.970 0.119 
 
Global cognition 14 -9.403 23 -5.866 49 -6.821 0.106 
Female 
        
 
Executive functioning 19 -3.001 47 -2.965 33 -2.151 0.089 
 
Working memory capacity 19 -2.454 47 -2.060 33 -1.668 0.001 
 
Episodic memory 19 -5.148 47 -2.419 33 -2.210 0.015 
 
Global cognition 19 -10.603 47 -7.444 33 -6.030 0.023 
P values were determined by independent samples Kruskal-Wallis H tests 
 
3.11 Relationship between education and plasma BDNF levels, in the old adults 
With the old adults displaying improved cognitive function with further progression of 
education, we investigated whether plasma BDNF levels were attributable to this 
difference. 
In the old adults, an increase of BDNF plasma protein trended (P=0.066) with the further 
the participants had progressed in their education, though no significant differences were 
seen in the stratified gender groups (Table 3.16). 
Table 3.16 Relationship between education and BDNF plasma protein, stratified by gender 
  
Basic School High School University   
BDNF plasma (Z-
Score) n Z-Score n Z-Score n Z-Score P 
  
       
 
Male 14 0.437 23 0.748 49 0.820 0.387 
 
        
 
Female 19 0.156 46 0.105 27 0.357 0.572 
 
        
 
Total 33 0.275 69 0.319 76 0.655 0.066 
P values were determined by independent samples Kruskal-Wallis H tests 
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3.12 Relationship between education and blood BDNF methylation, in the old 
adults 
In the old adults, it was observed that BDNF exon IV had reduced methylation at CpG sites 
3 and 4 in those who had progressed further into education, however, while there were 
reductions across the site, no other trend was close to being significant. BDNF exon I 
showed no changes between the groups (Table 3.17).  
Further analysis between the individual groups of basic and university education, showed 
a significant reduction in BDNF exon IV methylation in those with a university education 
(Mann Whitney U: CpG 3- P=0.026, CpG 4- P=0.018, CpG 5- P=0.022, Average 
methylation- P=0.035). 
Table 3.17 Relationship between education and BDNF methylation, in the old adults 
  
Basic School High School University 
 
  
n Methylation n Methylation n Methylation P 
BDNF Exon I 
        
 
CpG 1 15 0.400 36 0.263 25 -0.077 0.173 
 
CpG 2 15 0.533 36 0.788 25 0.166 0.442 
 
CpG 3 15 0.641 36 0.905 25 0.450 0.587 
 
CpG 4 15 0.605 36 0.885 25 0.592 0.810 
 
CpG 5 15 0.420 36 0.823 25 0.486 0.764 
 
Average 15 0.725 36 1.307 25 0.543 0.781 
BDNF Exon 
IV 
        
 
CpG 1 12 0.235 32 -0.004 29 -0.252 0.595 
 
CpG 2 12 0.384 32 -0.256 29 -0.170 0.278 
 
CpG 3 12 0.579 32 -0.025 29 -0.479 0.040 
 
CpG 4 12 0.675 32 -0.295 29 -0.573 0.045 
 
CpG 5 12 0.470 32 -0.353 29 -0.407 0.080 
 
CpG 6 12 0.261 32 -0.036 29 -0.092 0.733 
 
CpG 7 12 0.451 32 -0.354 29 -0.337 0.177 
 
CpG 8 12 0.119 32 -0.149 29 -0.449 0.670 
 
CpG 9 12 0.555 32 0.071 29 -0.313 0.417 
 
Average 12 0.642 32 -0.080 29 -0.307 0.135 
BDNF methylation is presented as a percentage, with Z-Scores based of the average of the young male and female 
populations separately. P values were determined by independent samples Kruskal-Wallis H tests. 
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3.13 Relationship between BDNF Val66Met genotype and cognition 
This study observed that the Val66Met polymorphism influenced cognitive function in the 
male population, in which the methionine substitution (AA/AG) was negatively associated 
with cognitive scores (Table 3.18). The negative association shown in the male population 
was preserved after controlling for age in working memory capacity and global cognition 
(Table 3.19, Figure 3.12).   
Table 3.18 Relationship between Val66Met genotype and cognitive function, stratified by 
gender. 
  
Male Female 
  
Val vs Met substitution 
 
Val vs Met substitution 
 
  
GG AA/AG P GG AA/AG P 
        Executive functioning -1.344 -2.183 0.016 -1.789 -1.566 0.489 
Working memory 
capacity -0.836 -1.571 0.001 -1.188 -1.328 0.646 
Episodic memory -1.740 -3.464 0.112 -1.742 -2.162 0.125 
Global cognition -3.920 -7.217 0.003 -4.719 -5.056 0.617 
P values were determined by independent samples Mann-Whitney U tests 
 
Table 3.19 Relationship between val66met genotype and cognitive function 
    Male Female Total 
    P P P 
    
    
  Executive functioning 0.152 0.118 0.857 
Working memory capacity 0.004 0.849 0.044 
Episodic memory 0.087 0.693 0.129 
Global cognition 0.018 0.865 0.137 
P values were determined by individual ANCOVAs, with age as a covariant 
 
 
 
 
 
 
 
 
 
55 
 
 
 
 
 
 
 
 
 
 
To determine whether the Val66Met polymorphism had a specific influence on cognitive 
ageing, the study further stratified by age (Table 3.20). Notably, the trend of reduced 
cognitive function with the methionine substitution remained in the old male adults, with 
a significant fall in working memory capacity (P=0.034). 
Table 3.20 Relationship between Val66Met genotype and cognitive function, stratified by age 
and gender. 
   
Male Female 
   
Val vs Met substitution Val vs Met substitution 
   
GG AA/AG P GG AA/AG P 
Young 
        
 
Executive functioning 0.210 0.001 0.197 -0.087 0.094 0.625 
 
Working memory capacity 0.270 -0.176 0.080 0.019 -0.221 0.295 
 
Episodic memory 0.033 0.157 0.458 0.166 -0.069 0.271 
 
Global cognition 0.513 -0.018 0.099 0.098 -0.196 0.538 
Old 
        
 
Executive functioning -2.510 -2.911 0.214 -3.015 -2.464 0.149 
 
Working memory capacity -1.666 -2.035 0.034 -2.057 -1.926 0.465 
 
Episodic memory -3.069 -4.671 0.475 -3.117 -3.293 0.402 
 
Global cognition -7.245 -9.617 0.117 -8.189 -7.683 0.690 
P values were determined by independent samples Mann-Whitney U tests 
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Figure 3.12. Relationship between BDNF Val66Met and cognitive function. Working memory capacity and 
global cognition were significantly higher in those who were GG homozygous (P=0.004 and P=0.018, 
respectively). Episodic memory was marginally higher in those who were GG homozygous (P=0.087). No 
significant difference was observed in executive functioning. 
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3.14 Relationship between BDNF Val66Met genotype and plasma BDNF levels 
When the BDNF protein in the plasma was compared between valine and methionine 
substitutions, no significant difference was observed in any group (Table 3.21, Figure 
3.13). 
Table 3.21 Relationship between val66met genotype and BDNF plasma protein 
    Male Female Total 
  
Val vs Met substitution Val vs Met substitution Val vs Met substitution 
BDNF plasma (Z-
Score) GG AA/AG P GG AA/AG P GG AA/AG P 
     
  
  
  
  Young -0.071 0.252 0.451 0.030 0.068 0.779 0.002 0.149 0.454 
Old 0.664 0.937 0.521 0.096 0.350 0.453 0.364 0.634 0.211 
Total 0.381 0.788 0.157 0.070 0.266 0.444 0.218 0.498 0.088 
P values were determined by independent samples Mann-Whitney U tests 
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Figure 3.13. Relationship between Plasma BDNF and BDNF Val66Met. 
No significant difference was observed between the genotypes. 
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3.15 Regulation of BDNF gene expression in the prefrontal cortex with age 
To gain a clearer understanding of the control of BDNF and its role in cognition we next 
focused on testing its regulation within the central nervous system, where BDNF is most 
biologically active. Therefore, this study tested brain material from the Dyne-Steele 
cohort, which had donated brains from participants who had been longitudinally studied 
for changes in cognitive function for around 30 years. Brains from all those participants 
who had died were studied for neuropathological changes revealing that they had passed 
away from AD related pathology or from causes that have no link to neurodegeneration 
(controls). 
While this cohort exclusively took samples from an aged population (>70 years old), the 
range of ages when the samples were taken still varied by 30 years (72-104 years old). 
Thus, BDNF gene expression from prefrontal cortex was correlated across the age of the 
participants upon death, controlling for neuropathology. It was observed that BDNF exon 
IV reduced significantly with age, while total BDNF expression showed a similar weaker 
reduction (Table 3.22, Figure 3.14).  
Table 3.22 Relationship between age and BDNF expression 
 
Age at death 
 
r P 
BDNF exon I expression -0.216 0.135 
BDNF exon IV expression -0.336 0.018 
BDNF total expression* -0.228 0.075 
r= Pearson correlation coefficient. *Spearman correlation 
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Figure 3.14. Relationship between BDNF expression and age. Left) Relationship between BDNF exon I 
expression and age, no significant association was observed. Middle) Relationship between BDNF exon IV 
expression and age, BDNF exon IV expression declined significantly with age (P=0.018). Right) Relationship 
between total BDNF expression and age, total BDNF expression declined marginally with age (P=0.075).  
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The expression of BDNF exon I varied significantly with gender (Female: -0.725, Male: 
0.146, P<0.001). Therefore, the analysis of BDNF exon I expression against age at death 
was split by gender, while controlling for neuropathology (Table 3.23). Although, no 
significant association was observed between age and BDNF exon I expression, in either 
males or females. 
Table 3.23 Relationship between age and BDNF exon I expression, stratified by 
gender 
  Age at death 
 
Male Female 
  r P r P 
BDNF exon I expression 
    
 
-0.392 0.133 -0.254 0.130 
r= Pearson correlation coefficient.  
 
3.16 Relationship between BDNF gene expression in the prefrontal cortex and 
cognition 
It was observed that BDNF exon I expression was negatively associated with baseline 
performances in memory and speed as well as being associated with a faster age-related 
decline in memory (Table 3.24). Even after controlling for age and neuropathology, BDNF 
exon I expression was still significantly associated with poorer memory scores and a faster 
rate of decline (ANCOVA: cross-sectional memory- β=-0.302, P=0.035; longitudinal 
memory- β=-0.388, P=0.008). 
  
Table 3.24 Relationship between BDNF expression and cognitive function 
 
BDNF exon I 
expression 
BDNF exon IV 
expression 
BDNF total 
expression 
 
r P r P R* P 
Cross-sectional fluid intelligence -0.234 0.092 -0.189 0.135 -0.039 0.754 
Cross-sectional vocabulary -0.149 0.287 0.028 0.825 -0.224 0.071 
Cross-sectional speed -0.313 0.024 -0.257 0.044 -0.077 0.547 
Cross-sectional memory -0.347 0.012 0.013 0.918 -0.187 0.136 
Longitudinal fluid intelligence -0.120 0.394 -0.128 0.313 -0.011 0.933 
Longitudinal vocabulary -0.164 0.241 0.009 0.945 -0.235 0.058 
Longitudinal speed -0.206 0.138 -0.204 0.105 0.073 0.563 
Longitudinal memory -0.385 0.004 -0.060 0.639 -0.194 0.118 
r= Pearson correlation coefficient. R*= Spearman correlation coefficient 
59 
 
 
We analysed BDNF expression against cognitive tests, in the healthy ageing group and AD 
group, separately, while controlling for age at cognitive testing (Table 3.25). In the healthy 
ageing group, BDNF exon IV expression was weakly associated with improved baseline 
memory and slower decline of memory. The opposite was observed in the AD group, as 
BDNF exon I and total BDNF expression were associated with impaired memory and a 
faster rate of decline in memory function. 
Table 3.25 Relationship between BDNF expression and cognition, stratified by Alzheimer’s 
Disease 
  
BDNF exon I 
expression 
BDNF exon IV 
expression 
BDNF total 
expression 
  r P r P r* P 
Age changes only 
      
Cross-sectional fluid intelligence -0.016 0.959 -0.087 0.779 0.139 0.634 
Cross-sectional vocabulary* 0.230 0.430 0.243 0.403 0.151 0.606 
Cross-sectional speed 0.171 0.576 0.318 0.290 0.104 0.722 
Cross-sectional memory 0.232 0.445 0.548 0.053 0.042 0.887 
Longitudinal fluid intelligence -0.069 0.823 -0.078 0.801 0.076 0.797 
Longitudinal vocabulary* 0.221 0.448 0.244 0.401 0.154 0.599 
Longitudinal speed 0.110 0.720 0.282 0.351 0.432 0.123 
Longitudinal memory 0.030 0.923 0.506 0.078 0.091 0.756 
AD 
      
Cross-sectional fluid intelligence -0.206 0.428 0.102 0.746 -0.111 0.670 
Cross-sectional vocabulary* 0.162 0.534 0.461 0.062 -0.103 0.694 
Cross-sectional speed -0.206 0.427 0.153 0.495 -0.219 0.399 
Cross-sectional memory -0.551 0.022 -0.174 0.132 -0.558 0.020 
Longitudinal fluid intelligence -0.051 0.845 0.142 0.926 0.056 0.832 
Longitudinal vocabulary* 0.085 0.746 0.375 0.138 -0.254 0.325 
Longitudinal speed -0.077 0.769 0.206 0.665 -0.018 0.947 
Longitudinal memory -0.618 0.008 -0.362 0.153 -0.458 0.065 
r= Pearson partial correlation coefficient. *=Spearman partial correlation. 
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3.17 Relationship between prefrontal cortex BDNF gene expression and 
neuropathology 
The average expression for each neuropathology group is displayed in Table 3.26. Analysis 
of BDNF expression between neuropathology groups found significant differences in 
BDNF exon I expression between the BRAAK groups (P=0.045), however post hoc analysis 
found no significant differences between the individual groups. There was also observed 
to be significant differences in BDNF total expression between the THAL groups (P=0.036), 
however post-hoc analysis showed no significant differences between the groups (Figure 
3.15). 
Table 3.26 Relationship between neuropathology and BDNF expression 
  
 
BDNF exon I expression 
BDNF exon IV 
expression 
BDNF total expression 
   n log n log n log 
THAL Group 
      
 
0 14 -0.363 17 -1.164 17 0.713 
 
1 9 -0.853 10 -1.009 10 -0.472 
 
2 6 -0.155 6 -0.840 6 -0.176 
 
3 11 -0.243 15 -1.010 17 0.676 
 
4 7 -0.624 9 -1.162 9 0.047 
 
5 6 -0.623 7 -1.026 7 0.160 
  P   0.479   0.991   0.036 
CERAD Group 
      
 
0 15 -0.399 18 -1.102 18 0.690 
 
1 16 -0.489 18 -0.822 18 -0.131 
 
2 14 -0.422 17 -1.249 18 0.153 
 
3 8 -0.593 11 -1.077 12 0.548 
  P   0.952   0.699   0.252 
BRAAK Group 
      
 
0 3 -0.173 4 -1.126 4 0.929 
 
1 24 -0.648 28 -1.104 28 0.144 
 
2 21 -0.179 24 -0.864 25 0.294 
 
3 4 -1.211 7 -1.492 8 0.584 
  P   0.045   0.582   0.697 
BDNF gene expression is presented as log. Neuropathology groups were previously devised from 
neuropathology scores. P values for BDNF exon I and BDNF exon IV expression were determined using One-
Way ANOVAs. P values for BDNF total expression were determined using Kruskal Wallis H tests 
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3.18 Correlation between methylation at individual CPG sites within promoters I 
and IV of the BDNF gene in the prefrontal cortex 
In the region analysed within the BDNF exon I promoter, the methylation of all the CpG 
sites were significantly correlated with one another (Figure 3.16, left, r>0.380, p<0.005). 
However, within the BDNF exon IV promoter region (Figure 3.16, right), there was no 
consistent pattern of correlation between the CpG sites. Therefore, an average 
methylation score could only be made for the BDNF exon I region. BDNF methylation was 
lower in the Dyne-Steele cohort than the MyoAge cohort (Table 2.1; 2.2, Methods).  
 
Figure 3.16. Spearman’s correlation between CpGs in BDNF exon I (left) and IV (right). All correlations within BDNF 
exon I were significant (p<0.005) 
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Figure 3.15. Relationship between BDNF expression and neuropathology. Left) Relationship between total BDNF 
expression and neurofibrillary tangle accumulation, total BDNF expression exhibits a minimal increase to 
neurofibrillary tangle accumulation, but decreases with further accumulation. Right) Relationship between BDNF exon 
I expression and β-amyloid accumulation, BDNF exon I expression increases in response to initial accumulation, but 
decreases with higher β-amyloid load.  
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3.19 Relationship between BDNF methylation and BDNF expression in the 
prefrontal cortex 
It was observed that methylation across the analysed BDNF exon I promoter was 
negatively associated with BDNF exon I gene expression (Table 3.27). No other 
associations were observed between methylation of the BDNF exon I or 4 regions and 
gene expression (Figure 3.17). When the healthy ageing group and AD group were 
analysed separately, BDNF exon I methylation showed a weak negative association with 
BDNF exon I gene expression, though no associations were observed in the AD group 
(Table 3.28). 
 
 
 
 
 
 
 
 
Table 3.27 Relationship between BDNF methylation and BDNF expression 
  
 
BDNF exon I 
expression 
BDNF exon IV 
expression 
BDNF total 
expression 
   r P r P r P 
BDNF exon I 
   
  
  
 
CpG 1 -0.060 0.685 -0.128 0.333 
 
CpG 2 -0.176 0.212 -0.145 0.251 
 
CpG 3 -0.230 0.105 -0.217 0.085 
 
CpG 4 -0.185 0.188 -0.007 0.959 
 
CpG 5 -0.021 0.885 -0.091 0.482 
 
Average* -0.273 0.051 -0.190 0.130 
BDNF exon IV 
       
 
CpG 1 
 
0.006 0.964 0.124 0.324 
 
CpG 2 -0.004 0.974 -0.195 0.143 
 
CpG 3 -0.177 0.161 0.071 0.574 
 
CpG 4 0.004 0.973 -0.171 0.173 
 
CpG 5 0.162 0.201 -0.200 0.111 
 
CpG 6 -0.067 0.639 0.159 0.261 
 
CpG 7 -0.049 0.698 0.121 0.336 
 
CpG 8 0.008 0.951 0.077 0.542 
 
CpG 9 -0.018 0.885 -0.205 0.101 
r= Spearman correlation coefficient. r*=Average methylation against BDNF exon I expression was tested using 
Pearson correlation 
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3.20 Relationship between BDNF methylation in the prefrontal cortex and 
cognition 
This study observed no significant associations between BDNF methylation and cognitive 
function, while controlling for age and neuropathology, in the Dyne-Steele cohort (Table 
3.29), although a weak association was observed between BDNF exon I methylation and 
faster decline of memory (Figure 3.18). 
Table 3.29 Relationship between BDNF methylation and cognitive function 
  
Cross-
sectional 
fluid 
intelligence 
Cross-
sectional 
vocabulary 
Cross-
sectional 
speed 
Cross-
sectional 
memory 
Longitudinal 
fluid 
intelligence 
Longitudinal 
vocabulary 
Longitudinal 
speed 
Longitudinal 
memory 
  r r r r r r r r 
BDNF 
exon I                 
CpG 1 0.005 0.077 -0.157 -0.307 0.024 0.047 -0.108 -0.136 
CpG 2 0.082 0.087 0.180 -0.279 0.129 0.106 0.271 -0.209 
CpG 3 0.057 0.177 -0.020 0.021 0.084 0.188 0.038 -0.017 
CpG 4 0.161 0.179 0.058 -0.046 0.188 0.177 0.063 -0.073 
CpG 5 0.143 0.088 0.103 -0.172 0.086 0.067 0.202 -0.243 
Average* 0.047 0.017 0.044 -0.225# 0.093 0.011 0.056 -0.189# 
BDNF 
exon IV                 
CpG 1 -0.135 -0.205 -0.048 0.098 -0.115 -0.208 -0.123 0.064 
CpG 2 -0.053 0.041 -0.081 -0.069 -0.074 -0.007 -0.001 -0.162 
CpG 3 -0.196 -0.053 -0.331 -0.142 -0.091 -0.093 -0.229 -0.077 
CpG 4 -0.161 -0.001 -0.069 0.175 -0.065 0.013 -0.081 0.073 
CpG 5 -0.088 0.080 -0.110 0.183 -0.106 0.033 -0.207 0.123 
CpG 6 0.021 0.129 0.300 0.141 0.032 0.098 0.318 0.141 
CpG 7 -0.016 -0.115 -0.148 -0.083 0.047 -0.157 -0.200 -0.105 
CpG 8 0.077 0.072 0.258 0.097 0.100 0.132 0.280 0.183 
CpG 9 0.019 0.258 0.207 0.205 0.115 0.223 0.100 0.335 
r= Spearman partial correlation coefficient. *Average methylation was tested using Pearson partial correlation. 
Highlighted correlations were significant at 0.05 level (P<0.05). No significance was observed in individual CpG 
sites after adjusting for multiple analyses. # BDNF exon I average methylation was weakly associated with cross-
sectional memory (P=0.068) and longitudinal memory (P=0.065). 
 
Table 3.28 Relationship between BDNF exon 1 methylation and BDNF expression, 
stratified by Alzheimer’s Disease 
 
BDNF exon I expression BDNF total expression 
  r* P r P 
Healthy Ageing         
BDNF exon I Average -0.474 0.074 -0.233 0.385 
Alzheimer’s Disease         
BDNF exon I Average -0.315 0.189 -0.044 0.826 
r= Spearman correlation coefficient. *Pearson correlation 
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We stratified the population between healthy ageing and AD, and reanalysed BDNF exon I 
methylation against cognitive function, controlling for age and neuropathology (Table 
3.30). No significant associations were observed in either group. 
Table 3.30 Relationship between BDNF exon I methylation and cognitive function, stratified by 
Alzheimer’s disease 
Cross-
sectional 
fluid 
intelligence 
Cross-
sectional 
vocabulary 
Cross-
sectional 
speed 
Cross-
sectional 
memory 
Longitudinal 
fluid 
intelligence 
Longitudinal 
vocabulary 
Longitudinal 
speed 
Longitudinal 
memory 
r r r r r r r r 
     Healthy ageing      
0.164 0.053 -0.217 -0.214 -0.053 0.089 -0.055 -0.089 
     Alzheimer’s Disease     
0.031 -0.164 0.045 -0.237 -0.075 -0.200 0.062 -0.240 
r= Pearson partial correlation coefficient.  No correlations were significant at 0.05 level (P<0.05). 
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Figure 3.18. Relationship between BDNF exon I methylation and longitudinal cognitive function. Top left) 
Relationship between BDNF exon I methylation and longitudinal fluid intelligence. Top right) Relationship between 
BDNF exon I methylation and longitudinal fluid vocabulary. Bottom left) Relationship between BDNF exon I 
methylation and longitudinal speed. Bottom right) Relationship between BDNF exon I methylation and longitudinal 
memory. No significant associations were observed, although increase methylation was weakly associated with a faster 
decline of memory (P=0.065). 
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3.21 Regulation of H3K27 acetylation at BDNF exon IV in the prefrontal cortex 
In light of the lack of association between BDNF exon IV methylation and BDNF 
expression in the brain, we considered an alternative epigenetic mark, histone H3K27 
modification. Specifically, we wanted to determine whether functional polymorphisms 
around the BDNF exon IV promoter affected the binding of H3K27Ac to the region. 
The rs56133711 polymorphism was considered the most informative choice based on its 
proximity to the BDNF exon 4 promoter and known H3K27Ac binding sites (Figure 1.5; 
Figure 3.19), as well as having a relatively high minor allele frequency (approximately 20% 
in the European population). It is characterised by a G/A conversion approximately 150 bp 
upstream of the BDNF exon IV. 
 
 
 
 
Figure 3.19. BDNF exon IV and rs56133711. The rs56133711 is 154bp upstream of BDNF exon IV and is located in a 
H3K27Ac binding region.  
We performed allele-specific ChIP analysis in brain to determine whether rs56133711 
differently associates with H3K27Ac (Figure 3.20). ChIP qPCR results showed that 
H3K27Ac was binding to BDNF exon IV (Figure 3.21). 
  
A 
G 
A G 
A (%) 
Input Pull-down 
Figure 3.20. Schematic of ChIP allele discrimination principles. Left) Allele discrimination. Histone H3K27ac 
is associated with an active chromatin state, therefore if the histone H3K27ac marker more readily binds to 
one of the rs56133711 alleles, then that allele could be associated with higher BDNF expression. Middle) 
Summary of ChIP (Murgatroyd et al, 2012). Anti-H3K27ac antibody binds to the H3K27ac marker, along with 
the sheared DNA that it is bound to. Immune complexes are cleaned, leaving only the bound DNA in the 
pull-down sample. Left) Results from sequencing rs56133711 heterozygotes. Input should be 50/50 A/G, 
however if allele discrimination is present, then the pull-down sample will be higher or lower than 50%. 
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Testing the ChIP pulldown with the different alleles it was observed that the H3K27Ac 
mark more readily interacted with the A allele than the G allele (Figure 3.22, Alternate 
strand sequenced: T nucleotide- input= 49.63%, pull-down= 72.25%, P=0.055). 
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Figure 3.21. Results of ChIP qPCR.  The higher signal relative to input of the H3K27ac  
pull-down in contrast to next to no signal displayed in the IgG sample, showed that 
H3K27ac was binding to the rs56133711 region, while the IgG  was not. 
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Figure 3.21. BDNF rs56133711 allele discrimination. A higher amount of T alleles 
were sequenced from the ChIP pull-down than the input samples (P=0.055), 
suggesting H3K27ac more actively binds to the rs56133711 A polymorphism. 
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3.22 Relationship between BDNF rs56133711 polymorphism and BDNF 
expression in brain 
With initial results showing that an interaction between rs56133711 and chromatin 
binding, we analysed whether this polymorphism related to expression of BDNF. 
However, when testing RNA levels across the brains with genotypes no significant 
association was seen between BDNF exon IV or BDNF total expression and the different 
alleles of BDNF rs56133711 (Table 3.31). 
Table 3.31 Relationship between BDNF rs56133711 and BDNF gene expression 
 
rs56133711 allele 
  AA (n=4) AG (n=27) GG (n=36) P 
     BDNF exon IV expression -0.159 -1.280 -0.994 0.127 
BDNF total expression 0.318 0.342 0.222 0.868 
P values were determined by a one-way ANOVA(BDNF exon IV) and a Kruskal-Wallis H test (BDNF total) 
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4. Discussion 
This study set out to analyse the different regulatory mechanisms that play a role in the 
expression of BDNF, with a focus on epigenetic regulation. Specifically, the aim was to 
determine whether these regulatory mechanisms are involved in cognitive ageing; 
observing the changes in DNA methylation with age, while deducing if these changes are 
contributing to reduced expression of BDNF, and subsequent cognitive decline. 
Moreover, this study compared the impact of various lifestyle factors on DNA 
methylation, determining whether both short and long term epigenetic changes were 
impacting the susceptibility of the population to age-related cognitive decline. It was also 
investigated how genetic variation in the BDNF gene could impact the regulation of BDNF, 
while determining if there were any downstream cognitive changes. Finally, we intended 
to analyse the interaction between the genetic and epigenetic mechanisms involved in 
the BDNF gene, whether there is any in the first instance, and if so whether it is 
attributable to cognitive function and ageing.  
4.1 Relationship between plasma BDNF and age 
Unexpectedly, BDNF levels measured in the plasma were significantly higher in the old 
adults than the young adults. With gender previously being reported as a potential 
cofounder of BDNF protein levels (Bus et al, 2011; Erickson et al, 2010), the population 
was stratified and it was revealed that the old male adults had significantly higher plasma 
BDNF protein than the young males, while there were no significant differences in the 
female population (Figure 3.2). A large body of research that had investigated the role of 
BDNF in cognitive ageing made this result surprising, especially since previous research 
has shown peripheral BDNF levels to decline with age (Lommatzsch et al, 2005; 
Ziegenhorn et al, 2007; Leckie et al, 2014; Shimada et al 2014). A previous study did 
describe a rise in peripheral BDNF with age (Bus et al, 2011), however it was found in the 
female population rather than the male population. Notably, all the examples of declining 
BDNF with age are derived from serum BDNF rather than plasma BDNF, which was used 
in this study. A recent study by Polacchini et al (2015) summarised the current methods 
for measurement of serum BDNF, noting that BDNF measurements are of limited value 
until reliable and replicable results can be produced. Furthermore, they suggested that 
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serum BDNF is potentially more reliable than plasma BDNF, supported by the observation 
that serum has a 100-fold higher concentration of BDNF than plasma (Radka et al, 1996). 
While this study measured relatively high plasma BDNF levels in comparison to the levels 
reported, they were still approximately 10-fold lower than the serum levels recorded in 
the previous studies. It has also been stated that due to BDNF protein being stored and 
secreted from platelets (Fugimura et al, 2002), the reproducibility of measurements could 
prove difficult, as simply inserting a needle into the plasma could trigger platelets to 
release stored BDNF. 
4.2 Relationship between plasma BDNF and cognitive function 
Due to the consideration that the clear majority of previous research has encountered a 
decline in serum BDNF with age, as well as the previous discovery that the MyoAge 
cohort displayed a negative correlation in cognitive function with age (Bradburn et al, 
2016), the study analysed whether BDNF was potentially attributable to cognitive ageing.  
No significant correlations were found between plasma BDNF levels and any of the 
cognitive functions in the MyoAge population (Table 3.1). When the population was 
further stratified by age, there was an observation that plasma BDNF levels were 
positively correlated with MMSE scores in the old females (Table 3.2). The MMSE scores 
were then shown to be positively associated with the cognitive scores obtained in the 
MyoAge cohort, an association that was also preserved specifically within the old female 
population. While the MMSE score represents a more general analysis of cognitive 
function than the CANTAB tests, it is capable of registering phenomena such as cognitive 
ageing and monitor neurological disease progression (Woodford and George, 2007). 
Similar tests are used to research cognition in various populations and have previously 
been associated with BDNF levels (Zou et al, 2014).  
A lack of association with between BDNF and cognitive function overall, as well as within 
sexes, weakens the hypothesis that BDNF could mediate age-related changes in cognitive 
functions. Despite this, BDNF levels appear to be protective against cognitive decline 
within the old female population, displayed by the positive association within the group. 
There is a profound amount of data on the positive role of BDNF on cognitive function 
(Croll et al, 1998; Egen et al, 2003; Blurton-Jones et al, 2009), which has led to the 
70 
 
hypothesis that BDNF is protective in age-related cognitive decline. This study suggests a 
gender specific role for BDNF as a protective mechanism against cognitive ageing, an 
observation that has been supported previously (Komulainen et al, 2008). Although no 
specific BDNF mediation on cognitive ageing was observed, it has been observed 
elsewhere (Erickson et al, 2010) and therefore, further research into this association and 
the mechanisms behind it are warranted. 
4.3 Relationship between blood BDNF methylation and age 
One such mechanism is BDNF methylation (McKinney et al, 2015). This study 
demonstrated that there was a highly significant increase in methylation at the promoter 
region of BDNF exon I with increasing age (Table 3.4). This was analysed further to find 
that the significant increase in methylation was only found in the old females compared 
to the young females, although the trend was also seen in the male population (Table 
3.5). It is known that DNA methylation varies with age, and that the variation depends 
upon the region of DNA, tissue source of DNA and the condition of the participants that 
DNA was collected from (Fraga et al, 2009; Marioni et al, 2015). Two interesting points of 
research have been published that have found that there is some correlation between 
BDNF methylation in the peripheral tissues and BDNF methylation in the hippocampus 
(Kundakovic et al, 2015) and the prefrontal cortex (Stenz et al, 2015). With regards to 
BDNF methylation, the picture is not as clear as expected, primarily due to much of the 
research being focused on neuropsychological and neurodegenerative diseases, 
specifically. This only enhances the importance of understanding the role of disease free 
ageing on BDNF methylation, as adequate healthy controls should be referred to when 
observing disease models. McKinney et al (2015) have previously shown that methylation 
of BDNF was higher in brains from older individuals than from younger individuals, 
supporting the data of this study, and presenting a model for BDNF methylation as a 
mechanism of age-related decline in BDNF expression. 
4.4 Relationship between BDNF methylation, BDNF expression and plasma BDNF 
levels 
No significant correlations were observed between BDNF exons I or IV and plasma BDNF 
levels in either males or females (Tables 3.6; 3.7). As previously stated, any age-
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associated changes in this cohort were not expected to be found due to the unexpected 
relationship shown between plasma BDNF and age (refer to section 4.1), although this 
further suggests that methylation at the promoter regions does not regulate peripheral 
BDNF levels. This does not rule out BDNF methylation as a regulator of plasma BDNF 
protein. Due to the crucial function and expression of BDNF across multiple tissues, there 
are nine functional promotors within the BDNF gene (Pruunsild et al, 2007), which 
through alternative splicing produce numerous transcripts. The different transcripts may 
be generated via varying cellular stimuli, and as a result may be localised and more stable 
within specific cells and sub-cellular compartments (Pruunsild et al, 2007; Cattaneo et al, 
2016). Cattaneo et al (2016), compared the expression of 12 of the main BNDF transcripts 
between peripheral blood cells and the hippocampus, where they found that transcripts 
including I, Va, Vb and VIIb were expressed in low levels in the peripheral blood, in 
comparison to the hippocampus. On the other hand, BDNF transcripts IV, IXabd and 
IXabcd were highly expressed in peripheral blood cells and the hippocampus. As CGIs are 
more frequently located upstream or around promoters, as observed with exons I and IV, 
BDNF methylation is still likely to contribute to the variation in transcript expression 
between tissues. This is supported by previous research that has displayed significant 
between-tissue variation in DNA methylation, including within the BDNF gene (Davies et 
al, 2012), although this is predominantly found in intragenic CGIs rather than promoter 
CGIs (Deaton et al, 2011; Davies et al, 2012).  
The function of intragenic DNA methylation is still controversial, as various reports have 
described its role in gene activation (Flanagan et al, 2007; Ball et al, 2009), as it may 
inhibit antisense transcripts that generate RNAi complementary to mRNA molecules. 
Alternatively, it may have a role in gene suppression, as Maunakea et al (2010) found that 
like promoter CGIs, intra- and inter-genic CGIs had CAGE clusters mapped to them, which 
are indicative of transcription start sites (Carninci, 2006), and therefore theorised that 
intragenic CGIs may in fact regulate alternative gene promoters. Further characterisation 
of intragenic methylation is required to elucidate its role within gene expression. 
Further analysis is recommended into the relation between BDNF methylation at the 
different BDNF exons and the BDNF transcripts, between tissues. As Cattaneo et al (2016) 
found, there appears to be more expression of BNDF transcripts IV, IXabd and IXabcd, and 
72 
 
so further methylation analysis should be carried out across the promoter and intragenic 
CGIS near to exons IV and IX. Even while this study failed to find an association with BDNF 
exon IV and plasma BDNF levels, a more widespread analysis than the region selected 
may provide a different picture.  
Variations in intragenic methylation between tissue types (Davies et al, 2012) appears to 
counteract the observations made by Kundakovic et al (2015) and Stenz et al (2015). This 
presents the immediate question: does BDNF methylation in the peripheral tissues 
predict biological changes in the brain as this author has previously suggested? With 
regards to Davies et al (2012), while it may be that there are tissue differences in 
methylation between most intragenic CGIs, promoter CGI methylation remained 
relatively conserved. Furthermore, it was noted that although it was mainly outweighed 
by between tissue variation, between individual variation in DNA methylation was 
correlated between brain and blood, suggesting that peripheral methylation might still be 
useful as a biomarker for the changes seen in some neurological conditions. Since BDNF 
methylation at promoters has been shown to inhibit gene expression (Klose and Bird, 
2006; Cedar and Bergman, 2009), between individual variation occurring at these sites 
could present a clear pathway for peripheral methylation to mirror CNS methylation, 
highlighting changes in expression within the brain. This could also be said of intragenic 
methylation once more is understood about its function. Peripheral BDNF methylation in 
particular may be more relevant to neurological function, as BDNF actively crosses the 
BBB (Poduslo et al, 1996; Pan et al, 1998). Even though this is a two-way flow, it suggests 
that BDNF generated peripherally contributes at least in some way to BDNF within the 
brain. 
4.5 Relationship between blood BDNF methylation and cognitive function 
It is because of these reasons that we studied the role of BDNF methylation as a 
biomarker of cognitive function. This study observed a significant negative association 
between BDNF exon I methylation and executive functioning, with further weaker 
negative associations with working memory capacity and global cognition (Table 3.8). It 
appears that this negative association is attributable predominantly to the male 
population, with no associations observed within the female population (Table 3.9). In 
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addition to the association across the total male population, it was found that BDNF exon 
I methylation had a strong negative correlation with executive functioning and working 
memory capacity within the old male population (Table 3.10). These both suggest that 
DNA methylation is having a gender specific effect on the BDNF gene which is impacting 
cognitive function. Specifically, we theorise that BDNF methylation at exon I is reducing 
the generation of the BDNF exon I transcript, leading to a reduction in BDNF expression. 
This is hampering the ability of BDNF to maintain neuroplasticity required for healthy 
brain function and processing, which is displayed in the reduced cognitive scores. 
Interestingly, BDNF exon I methylation increased with age, albeit the association was 
weak, and so to some extent could be contributing to the cognitive ageing found within 
the population. To our knowledge, this is a novel observation of a background mechanism 
to cognitive ageing, although this is a tentative speculation that would require further 
research. However, to some extent this could bridge a gap seen within the analysis of 
BDNF methylation and cognitive ageing in which: 1) BDNF methylation has been 
associated with learning and memory function (Lubin et al, 2008; Roth et al, 2009), 2) 
BDNF methylation is a predictor of AD risk (Chang et al, 2014; Xie et al, 2017), 3) BDNF 
expression is associated with age-related decline in cognitive function (Komulainen et al, 
2008; Erickson et al, 2010). Our identification of an age-associated reduction in BDNF 
methylation that is linked with cognitive decline, could potentially link this information 
together, while we further suggest that increased BDNF methylation could lead from 
healthy cognitive ageing into the progression of neurodegeneration.  
4.6 Relationship between physical activity and BDNF regulation in the old adults 
With DNA methylation and other epigenetic modifications providing some of the 
explanation for how environmental factors impact our genes and cause subsequent 
phenotypic changes, we considered lifestyle factors that have previously been linked with 
cognitive function, and analysed their impact on BDNF methylation.  
Exercise is one such intervention that has been observed to reverse some of the cognitive 
deficit associated with ageing (Weuve et al, 2004; Ruscheweyh et al, 2011; Blondell et al, 
2014). Therefore, we initially tested the cognitive function of the old population, between 
the participants who were classified as physically active and those who were inactive. No 
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significant differences were found in any of the cognitive functioning scores between the 
active and inactive groups, which is opposed to what has previously been investigated 
(Table 3.11). A significant amount of research has shown exercise to produce a number of 
positive changes in neurological function, and the mechanism by which this is achieved is 
well categorised (Marosi et al, 2014), however it is not clear whether there is a minimum 
exercise requirement to induce these changes. Previous studies have used exercise 
interventions that had a similar level of exercise regime to what was required to be in the 
MyoAge physically active group (Erickson et al, 2011), and had shown improvements in 
memory. This suggests that the MyoAge population appear to be undergoing sufficient 
aerobic exercise required to induce neurological changes. Research from the same 
intervention experiment have also reported improvements in executive function 
mediated by changes in serum BDNF levels (Leckie et al, 2014), but interestingly observed 
that these improvements were most pronounced in participants over 71 years of age. This 
suggests that this mechanism of action may only be significant to participants who 
already have neurological changes within their brain, that is inhibiting its function, and 
which may be the precursor to further cognitive decline or neurodegeneration. The old 
adults in the MyoAge cohort are all community-dwelling and high performing regardless 
of their classification of physical exercise, and have displayed no signs of 
neurodegeneration.  
It is possible that exercise within the old population of the MyoAge group could still be 
inducing the molecular pathways that have been shown to improve cognitive function, 
and that it still may be helping them maintain a certain level of neurological health that 
could in the future counteract further progression of neurological decline. As BDNF has 
been widely shown to be one of the key mediators of these interventions (Erickson et al, 
2011; Ruscheweyh et al, 2011; Leckie et al, 2014; Marosi et al, 2014), we studied the 
association of plasma BDNF with activity levels in the old population. Contrary to the 
majority of information, there were no significant differences between the active and 
inactive populations. While this result was not expected, our previous findings with 
unexpected associations with plasma BDNF levels meant it was not surprising. Further 
analysis will be required to decide whether the plasma BDNF readings are true 
representations of the MyoAge cohort, and whether they present a true difference to 
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information already published. A possible consideration is that a lot of research is on 
exercise interventions that are observed over a relatively short period. Hopkins et al 
(2011) investigated the effect of voluntary exercise between groups of adolescent and 
adult rats. The exercise intervention showed increased BFNF levels and improved novel 
object recognition, which is in line with the other research, however, when the old rats 
were tested two weeks after the intervention, it was found that these changes had 
reverted back to their previous levels. Therefore, maintained levels of exercise over a long 
duration should be considered in further investigation of cognitive intervention.  
The study took into consideration the observations of changes in BDNF levels from 
previous studies, as well as the fact that the exercise levels in our physically active group 
were well maintained across a long duration. From this, we decided that if underlying 
epigenetic mechanisms were contributing to the changes previously observed, then there 
might be changes in BDNF methylation between the old active and inactive populations in 
the MyoAge cohort. When this was investigated, it was found that BDNF exon IV 
exhibited more methylation in the inactive population, but perhaps strikingly, the old 
active population had lower BDNF exon IV methylation than even the young population 
(Table 3.12). This was partly explained when the old population was stratified by gender, 
as within the female population both the active and inactive groups had lower BDNF exon 
IV methylation scores than the young population (Table 3.13). This trend was not picked 
up in previous analyses as no significant difference was shown between young and old 
females. While the difference is statistically negligible, the reduced BDNF methylation 
with age is opposite to the raised methylation levels witnessed in this study, in BDNF exon 
I, and others (McKinney et al, 2015), which goes to show methylation is a dynamic 
process which does not interact equally across the genome. Even with this surprising 
observation, the old female population still exhibited reduced methylation levels in the 
active population than the inactive. In addition, we distinguished that the old female 
population also had reduced BDNF exon I methylation in the active population, although 
this was a weaker association. This suggests that there is a gender specific role for 
exercise to reduce the levels of methylation at the promoters of the BDNF gene. While it 
has not been observed within this study, this suggests BDNF methylation as a potential 
underlying mechanism for how exercise increases BDNF transcript expression (Oliff et al, 
76 
 
1998; Vaynman et al, 2004) and subsequent BDNF expression (Erickson et al, 2011; 
Ruscheweyh et al, 2011; Leckie et al, 2014; Marosi et al, 2014). Further investigation must 
be done to develop understanding of how epigenetic regulation mediates exercise-
associated increases in BDNF levels, but this result has also been established in rat 
models. Gomez-Pinilla (2011) has found that exercise reduces methylation of BDNF 
promoter IV, like our findings, while further showing that exercise increased the levels of 
phosphorylated MeCP2, CREB and activated CaMKII, which are associated in the 
regulation of BDNF (Vaynman et al, 2003; Zhou et al, 2006). They also showed that 
exercise enhanced the binding of acetylated histone 3 at BDNF promoter IV, which again 
is associated with increased BDNF expression (Tsankova et al, 2006; Tian et al, 2010). 
Taken together, these findings present the epigenetic regulation of the BDNF gene as a 
potent mediator of exercise-association changes in BDNF expression, which might be 
attributable to improvements in cognitive function. 
4.7 Relationship between education and BDNF regulation in the old adults 
Where physical exercise is an environmental stimulus that can produce short-term 
epigenetic alterations that impact cognitive function, education is proposed to produce 
more long-term alterations to neurological function that can impact cognitive function 
years after the event has taken place. However, it has been observed that education is 
associated with higher cognitive functioning in older age only when neuropathology is 
absent or mild, whereas with the onset of neurodegeneration, education does not slow 
the rate of cognitive decline (Koepsell et al, 2008; Zahodne et al, 2011; Arenaza-Urquijo et 
al, 2017). A reason for this is that education is one of a group of factors which contribute 
to a brain and cognitive reserve (Stern, 2009; Stern, 2012; Franzmeier et al, 2017) that 
involve two key concepts. 1) Brain reserve is the passive model where increases in brain 
size, neuronal density and synaptic connections allow the brain to maintain more 
advanced neuropathology before symptoms are expressed and 2) Cognitive reserve is a 
more active model in which pre-existing cognitive processes are called upon as 
compensation to cope with the dysregulation of other pathways affected by 
neuropathology (Stern et al, 2002). To test this theory, we analysed the effect that prior 
education attainment had on current cognitive functioning in the old adults. It was 
observed that there was a significant trend in which the further a participant had 
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progressed in their education, the higher their cognitive functioning scores were (Table 
3.14). This association was only observed within the female population however, while 
the male population did not show a significant trend across all the education groups, they 
did display a weaker improvement in cognitive functioning in those who had achieved a 
university education compared to those who had achieved a basic education (Table 3.15). 
This agrees with previous research that within a healthy ageing cohort, education 
contributes to these reserves and improves cognitive functioning in later life.  
It has been previously observed that BDNF plays a significant role in developing cognitive 
reserves (Stern, 2012; Ward et al, 2015; Buchman et al, 2016). This appears to be due to 
BDNF’s involvement in promoting synaptic plasticity and LTP (Lu et al, 2013; Bekinschtein 
et al, 2014), that are also important for BDNF’s role in learning and memory (Egan et al, 
2013; Cunha et al, 2010). When BDNF was analysed against measures of education in the 
MyoAge cohort, a weak trend was observed in the total population, that plasma BDNF 
levels were increased in the participants who had progressed with their education (Table 
3.16). This appears to support the results previously acquired, but caution should be 
exercised as to how much of an effect plasma BDNF has over brain and cognitive reserves. 
Though as previously mentioned BDNF does actively cross the blood brain barrier 
(Poduslo et al, 1996; Pan et al, 1998).  
While this study did display minor associations between plasma BDNF levels and 
educational attainment, there were three key lines of thought that prompted our analysis 
of BDNF methylation and education, which are related to our considerations for BDNF -
methylation and cognition (Section 4.5). Firstly, BDNF methylation has been associated 
with learning and memory in a lifelong manner (Lubin et al, 2008), therefore any 
epigenetic changes during early life exposures such as education may be preserved to 
some extent for a long duration (Kundakovic et al, 2015). Secondly, BDNF expression is 
associated with protection against cognitive decline (Buchman et al, 2016), suggesting it 
has some association with cognitive reserve. Thirdly, BDNF promoter methylation has 
been suggested to be a risk factor for AD, meaning that BDNF methylation might be 
inhibiting the ability of BDNF to contribute to the brain and cognitive reserves, resulting in 
an increased incidence of AD. When we analysed BDNF methylation against educational 
attainment, we observed some weak reductions in BDNF exon IV methylation with the 
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further the participants had progressed with their education (Table 3.17). There was a 
significant reduction in BDNF exon IV methylation in participants who had attained a 
university education compared to those who had achieved a basic education. We believe 
that there are two mechanisms in which education-associated changes in BDNF 
methylation may predict cognitive function in later life. Exposure to education and similar 
neurological enrichment appears to reduce the amount of methylation on the promoters 
of the BDNF gene, allowing increased BDNF expression to aid memory consolidation 
(Lubin et al, 2008). This firstly increases neurogenesis, LTP and synaptic density within the 
brain (Lu et al, 2014), enriching the brain and cognitive reserve that is maintained across a 
lifetime (Stern, 2012). These reserves are displayed with higher cognitive capabilities in 
old age. Secondly, BDNF methylation appears to be maintained to some extent across a 
lifetime (Kundakovic et al, 2015; Unternaehrer et al, 2015), therefore early changes in 
methylation could underlie long-term changes in BDNF gene expression. Higher BDNF 
gene expression as a result might provide protection in later life against cognitive ageing 
and neuropathology (Buchman et al, 2016). This theory is admittedly wide spanning and 
partially speculative, with many limitations, including only a cross-sectional analysis of 
BDNF methylation, a still uncertain understanding of the relationship between peripheral 
methylation and biological function in the brain and relatively small methylation changes. 
However, we believe there is enough supporting research to warrant further 
investigation. 
4.8 The role of the BDNF Val66Met genotype in cognition 
Epigenetic stimuli are not the only means of regulating BDNF expression, as genetic 
factors such as common genetic variants have been established as influencing the 
biological pathway of BDNF. The SNP rs6265 (Val66Met) results in a valine to methionine 
substitution at codon 66 in the pro-domain of BDNF which directly affects the structure of 
pro-BDNF, inhibiting the activity-dependent secretion of BDNF (Chen et al, 2004). It has 
been widely implicated in affecting cognitive function (Egan et al, 2003; Hariri et al, 2003; 
Kambeitz et al, 2012; Ward et al, 2015) and brain morphology (Kambeitz et al, 2012), as 
well as moderating age-associated cognitive decline (Miyajima et al, 2008; Sublette et al, 
2008; Erickson et al, 2008; Lim et al, 2013). Results from this study displayed a significant 
reduction in working memory capacity, as well as a weaker reduction in executive 
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functioning, in participants who were either Val/Met heterozygous or Met/Met 
homozygous, in the male population (Table 3.18). Specifically, the old male population 
had a significant reduction in working memory capacity in participants who were either 
Val/Met heterozygous or Met/Met homozygous (Table 3.20). This result supports the 
research that has found that BDNF Met carriers perform worse on tests of cognitive 
function and memory (Egan et al, 2003; Miyajima et al, 2007; Nagel et al, 2008; Lim et al, 
2013). On the other hand, we did not find that Val/Met heterozygous or Met/Met 
homozygous perform worse on fluid intelligence and executive functioning (Sapkota et al, 
2017). A number of studies have found that the Val allele is indicative of increased age-
related cognitive decline (Erickson et al, 2008; Nagata et al, 2012), and a recent meta-
analysis compounds the inconsistent findings presented in the literature (Mandelman and 
Grigorenko, 2012). There are various reasons for these discrepancies that should be 
considered in future investigations, including, the heterogeneity of Val66Met amongst 
different ethnic populations, age of the participants, association with other genotypes 
(Wollam et al, 2015) and the interaction of Val66Met with environmental stimuli across a 
lifespan.  
We considered whether the association between the Val66Met polymorphism and 
cognitive functions found in the MyoAge cohort was attributable to changes in BDNF 
expression. When this was analysed, it was found that there were no significant changes 
in plasma BDNF levels between participants who were Val/Val homozygous and those 
who were either Val/Met heterozygous or Met/Met homozygous (Table 3.21). This 
appears to be in agreement with previous observations (Egan et al, 2003; Chen et al, 
2006; Frielingsdorf, 2010), although there has been some suggestion that the Met allele is 
associated with reduced BDNF levels (Ozan et al, 2010). This may be due to the different 
secretion mechanisms of peripheral cells compared to neuronal cells, as the Met allele 
only has been shown to effect depolarization-dependent secretion (Egan et al, 2003). So, 
an effect of the BDNF Val66Met polymorphism on peripheral BDNF levels might not be 
replicated within the brain.  
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4.9 Relationship between BDNF gene expression in the prefrontal cortex and age 
As previously described, BDNF has been observed to be influenced in an age-dependent 
manner (Erickson et al, 2010; Leckie et al, 2014). Notably, the majority of research into 
BDNF, including the work of this study in the MyoAge cohort, has been performed in the 
peripheral systems. This can provide great insight into the role of BDNF, however, since 
BDNF is most biologically active within the brain, we analysed the expression of BDNF 
from prefrontal cortex samples from the Dyne-Steele cohort, as described previously. 
Although, the Dyne-Steele population consists of one age group, there was still an age 
range of over 30 years, and therefore we considered whether there were late onset age-
associated changes in BDNF gene expression across the old population. Since age is the 
greatest risk factor for the onset of AD (Alzheimer’s Association, 2017), we controlled for 
neuropathology within the analysis. This study found that there was a negative 
association between age and BDNF exon IV expression, as well as a weaker negative 
association between BDNF total expression, both of which were not attributed to 
neuropathology onset (Table 3.22). It has previously been well described that BDNF 
expression declines with age, both in healthy ageing (Croll et al, 1998; McKinney et al, 
2015; Oh et al, 2016) and ageing associated with neurodegeneration (Tapia-Arancibia et 
al, 2008; Zuccato and Cattaneo, 2009). While our results agree with the consensus, we 
have also shown that BDNF expression maintains a negative association with age within 
an old population (72-104 years old), regardless of neuropathology.  
4.10 Relationship between BDNF gene expression in the prefrontal cortex and 
cognition 
Whereas other studies have compared BDNF gene expression between young and old 
populations, this study has shown that BDNF expression continues to decline with 
advancing age. Since BDNF has been associated with age-related cognitive decline 
(Komulainen et al, 2008; Erickson et al, 2010), we hypothesised that continued reduction 
in BDNF gene expression in later life may be responsible for the continued or accelerated 
cognitive decline observed in old age (Laske et al, 2011; Forlenza et al, 2015). This study 
showed that there was a significant association between BDNF exon I expression and 
impaired performances in memory and speed tests, as well as with a faster rate of decline 
in memory (Table 3.24). This finding is unexpected as it suggests that increased brain 
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BDNF expression is contributing to poorer memory performances. Considering that it is 
still not established what role neuropathology has in altering the BDNF mechanism, and 
that dementia induces a faster rate of cognitive decline than in normal ageing (Yu et al, 
2012), we concluded that controlling for neuropathology was not enough to account for 
variation in BDNF expression and cognitive decline between the healthy ageing and AD 
groups. To test whether there are differences in the BDNF mechanism between these 
ageing groups, we stratified the population between healthy ageing and AD, and 
reanalysed BDNF expression against cognitive function. In the neurologically healthy 
population, it was shown that BDNF exon IV expression was weakly associated with 
improved memory as well as a slower decline in memory. Strikingly, BDNF expression 
appears to have a different function in AD, as it was observed that BDNF exon I and total 
BDNF expression are detrimental to performances in memory tests, as well as being 
associated with a faster rate of decline of memory (Table 3.25). This suggests that the 
biological mechanism of BDNF is different between healthy and disease-associated 
neurological ageing, and might be altered to compensate for neurodegeneration. Due to 
the inaccessibility of the brain during longitudinal testing, there are limited results on the 
role of BDNF in the brain during ageing. Various studies have shown that peripheral BDNF 
levels are associated with improved cognitive function and slower decline (Komulainen et 
al, 2008; Laske et al, 2011), including our own. It is still uncertain how peripheral BDNF 
levels predict function with the brain, although it has been associated with an age-
associated decline in hippocampal volume (Erickson et al, 2010). For the healthy ageing 
group, our findings appear to support observations previously made that increased BDNF 
expression (Hattiangady et al, 2005), and BDNF gene expression (Tapia-Arancibia et al, 
2008; Oh et al, 2016) in the brain are associated with an improved outlook regarding age-
associated cognitive decline. Conversely, our findings from the AD group vary from what 
has previously been observed. Buchman et al (2016) analysed the BDNF gene expression 
from a cohort of over 500 older adults who had underwent longitudinal cognitive testing, 
clinical testing for AD and post-mortem neuropathological testing. They found that higher 
BDNF expression is associated with reduced rates of cognitive decline, however this 
association was strongest in the participants with Dementia, whereas they found no 
significant association between BDNF expression and cognitive decline in participants 
with no cognitive impairment. This suggests that BDNF works as a compensatory 
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protective mechanism against the damage caused by neurodegeneration. While our 
results contrast with this, we hypothesised that the association of BDNF expression with 
faster rates of memory decline might also be due to compensation rather than causation 
(Diniz and Teixeira, 2011). Our reasoning behind this is that BDNF expression was 
predominately associated with worse memory results in the AD group, however apart 
from one association with a faster rate of decline in vocabulary, there were no other 
associations observed. The faster rates of memory decline are indicative of hippocampal 
and cortical atrophy (Dubois et al, 2014) associated with AD, therefore the affected and 
surrounding neurons might increase expression of BDNF in an attempt to induce 
neurogenesis to compensate for damage (Budni et al, 2015; Song et al, 2015). Burbach et 
al (2004) found that BDNF mRNA was being upregulated around the tissue surrounding 
plaques, as well as significant increases in cortical BDNF levels with increased β-amyloid 
load. There are still inconsistences across multiple investigations into the role of BDNF in 
AD (Song et al, 2015), suggesting that there are factors not being considered in this 
relationship. The differences in BDNF responses shown between our study and Buchman 
et al (2016) may be due to the multifactorial nature of AD. Accumulated neuropathology 
might simply overwhelm BDNF compensation, or there might be genetic differences 
between European and American populations that alter the response of BDNF in AD. 
Overall, there appears to be a growing consensus that BDNF is protective against both 
normal and AD neuronal ageing, and further research is essential to understand how 
BDNF interacts with all systems of the brain, including inflammation (Calabrese et al, 
2014), in response.  
4.11 Relationship between BDNF gene expression in the prefrontal cortex and 
neuropathology 
To further our understanding of the reasons why BDNF expression was associated with 
impaired memory and faster decline in the AD group, we analysed the association 
between BDNF expression and neuropathology, in order to determine whether BDNF was 
responding to the accumulation of plaques and neurofibrillary tangles (Burbach et al, 
2004). We determined that there were significant differences in total BDNF expression 
with increased β-amyloid load (Thal), as well as this there were significant differences in 
BDNF exon I with increased neurofibrillary tangles (Braak) (Table 3.26). Further post-hoc 
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analysis found that there were no significant difference between the individual groups. 
Nevertheless, they both showed interesting trends with initial accumulation of β-amyloid 
and neurofibrillary tangles inhibiting BDNF expression, only for BDNF expression to 
recover during intermediate neuropathology, however BDNF expression again falls with 
advanced neuropathology (Figure 3.14, results). While the trend is statistically weak, 
there is evidence to support it, such as changes in BDNF around the tissue surrounding 
plaques have been observed (Burbach et al, 2004). Zussy et al (2011; 2013) have 
previously observed that BDNF is significantly responsive to cerebral β-amyloid injection, 
significantly increasing in the prefrontal cortex and hippocampus 1 week after injection, 
and then decreasing in the ensuing weeks. This transient response has been shown to 
partially compensate for the damage to neurons caused by β-amyloid (Rantamäki, 2013), 
as well as inhibiting the generation of β-amyloid (Gralle et al 2009; Rohe et al 2009). As 
we have suggested, β-amyloid affects the function of BDNF within the brain (Meng et al, 
2013; Zussy et al 2013). It appears to inhibit the PI3K-Akt-mTOR signalling pathway 
downstream of BDNF-TrKB binding (Jimenez et al, 2011), interfering with the support 
BDNF provides to neuronal plasticity and survival. Moreover, β-amyloid directly inhibits 
BDNF transcription by interfering with the activation of CREB, stopping it from binding to 
the BDNF promoters (Meng et al, 2013; Liu et al, 2013; Palomer et al, 2016). While BDNF 
is reactive to β-amyloid and actively works to combat it, β-amyloid also inhibits BDNF. Our 
results appear to support this balance, with initial β-amyloid accumulation overwhelmed 
by increased expression of BDNF, however further accumulation of β-amyloid tips the 
scales and BDNF expression is suppressed, leading to further acceleration of 
neurodegeneration. This supports our findings of altered BDNF expression between 
healthy ageing and AD, as in healthy ageing, any presence of neuropathology is countered 
by increased BDNF expression, therefore BDNF is not inhibited from its normal promotion 
of neurogenesis and synaptic plasticity. In AD, neuropathology has progressed to a point 
where it is overwhelming the compensatory mechanism of BDNF, while BDNF continues 
to be upregulated in a crisis response to the accumulated damage, although its function is 
being inhibited. While, this might improve the understanding of the differences between 
age-associated cognitive decline and AD, it is still a microcosm of the neurological 
condition. Therefore, research should progress to investigate this relationship. 
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4.12 Relationship between BDNF methylation and BDNF gene expression in the 
prefrontal cortex 
Since we have observed a mechanism for BDNF methylation to mediate the decline in 
BDNF in the plasma, and that it was attributable to age-associated cognitive decline in the 
MyoAge cohort. We tested the same principle in the prefrontal cortex to determine if 
methylation is associated with BDNF expression in the brain. As expected BDNF 
methylation was lower in the prefrontal cortex (Dyne-Steele) than the blood (MyoAge), 
indicating higher levels of BDNF expression in the brain. It was observed that there was a 
weak negative association with BDNF exon I methylation and expression (Table 3.27). 
Notably this association was only preserved, albeit weakly, in the healthy ageing group, 
while no significant association was found in the AD group (Table 3.28). This suggests that 
the normal epigenetic regulation of BDNF is deregulated or bypassed in AD. Various 
neurological disorders have been shown to affect BDNF methylation (Roth et al, 2009; 
2011; Autry and Monteggia, 2012), showing that BDNF methylation is susceptible to 
adverse environments. Whereas the effect of AD on BDNF methylation remain 
inconsistent, with both findings of higher (Chang et al, 2014; Nagata et al, 2015) and 
unchanging (Bakulski et al, 2012; Carboni et al, 2015) methylation levels in AD. A negative 
association between BDNF methylation and BDNF expression in an older group has been 
reported previously (Keleshian et al, 2013), but no previous reports of differences in BDNF 
methylation between control and AD participants was found. Mastroeni et al (2010) 
found that various epigenetic markers and regulators, including DNMT1 and the 
MeCP1/MBD2 methylation complex, were significantly decreased in AD, suggesting that 
AD does directly interfere with epigenetic regulation. While only observed in one of the 
BDNF transcripts, the change in association between BDNF methylation and expression 
from healthy ageing to AD, may indicate that the BDNF epigenetic regulation is 
compromised in AD. From another perspective, AD may induce transcriptional and 
posttranscriptional alterations that bypass the epigenetic regulation, such as how β-
amyloid inhibits CREB activation and subsequent BDNF activation (Meng et al, 2013; Liu et 
al, 2013). Caution should be exercised with this observation until further investigation has 
taken place, as the low numbers may inhibit a significant observation being observed in 
the AD group. 
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4.13 Relationship between BDNF methylation in the prefrontal cortex and 
cognition 
BDNF exon I methylation was observed to be weakly associated with worse baseline 
memory scores and a faster rate of decline in memory (Table 3.29). As BDNF methylation 
at the promoter sites inhibits transcription of BDNF, this supports the hypothesis that 
higher BDNF methylation would limit the expression of BDNF, and its neurotrophic 
properties. While the two populations are separate, this finding supports our observation 
from the MyoAge cohort. The differences between BDNF methylation in AD and healthy 
ageing remain inconclusive, as described above, but the current body of literature 
appears to show BDNF methylation as a risk factor for further cognitive decline and 
progression to AD (Xie et al, 2017). We observed above that AD neuropathology might 
also influence the relationship between BDNF methylation and expression and therefore 
we attempted to determine whether this was mirrored in the association with memory. 
However, no significant associations were observed in either group (Table 3.30).  
4.14 Regulation of H3K27 acetylation at BDNF exon IV in the prefrontal cortex 
There are additional epigenetic regulatory mechanisms aside from DNA methylation such 
as chromatin and histone marks. Therefore, considering the lack of associations between 
BDNF exon IV methylation and BDNF expression in the brain, and the relatively low levels 
of methylation at this locus in the brain (Table 2.2, Methods), another epigenetic marker, 
histone H3k27 modification, was considered as a potential mediator of BDNF exon IV 
expression. This marker is usually associated with active gene transcription. (Palomer et 
al, 2016). In addition, we considered the possible role of polymorphisms in regulating 
epigenetic control of BDNF, i.e. the genetic-epigenetic interaction that may be involved in 
BDNF expression. Our choice of rs56133711 was based on its high frequency in the 
European population and it was the closest functional polymorphism to BDNF exon IV and 
H3K27Ac binding sites. After we found that H3K27Ac was binding to the BDNF exon IV 
promoter region, we performed allelic specific ChIP pulldown, in which we found that the 
H3K27Ac marker associated more with the A allele of rs56133711 (Figure 3.21). This 
suggests that the polymorphism does affect H3K27Ac binding. As H3K27Ac is associated 
with active gene transcription (Palomer et al, 2016), we next considered whether this 
allele specific association contributed to BDNF expression. However, we found no 
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association between polymorphism and gene expression (Table 3.31). Although no 
statistical significance was found, this points to the multiple regulation mechanisms that 
need to be considered within BDNF expression. Most likely activity dependent promoters 
such as BDNF exon IV require more complex regulation than simply associating with 
either methylation, histone acetylation or other factors individually.  
4.15 Limitations 
Several important limitations of the study need to be mentioned. With the MyoAge 
cohort, while taking peripheral measurements allowed for DNA and protein samples to be 
taken at a close timepoint to cognitive testing, the functionality of peripheral BDNF as a 
biomarker for cognitive decline remains inconclusive. Also, cross-sectional cognitive 
testing limited the studies ability to draw conclusions relating to cognitive decline.  
The Dyne-Steele cohort had relatively low numbers in comparison to some other studies 
observing BDNF in the brain, reducing the power of our findings, especially when we 
stratified the population. The fact that different time points were used for cognitive 
testing and molecular testing of the prefrontal cortex should be considered when 
observing any associations between BDNF and cognition. Furthermore, it is inconclusive 
how much of an effect small changes in methylation, even around promoters, has on 
transcription. 
4.16 Summary 
Even with these considerations, there are many implications that can be drawn from this 
study. We have contributed further to the hypothesis that BDNF methylation contributes 
to cognitive ageing, and could potentially lead to further risk of AD. Factors such as 
exercise and education can affect BDNF methylation throughout life, which may 
contribute to the varying presentations of cognitive ageing and AD. Moreover, AD inhibits 
the function of BDNF and interferes with the epigenetic regulation of BDNF. BDNF 
methylation inhibits BDNF expression and cognitive function in older age, but these 
observations are weaker in AD. We have also found a novel genetic-epigenetic 
interaction, which could further contribute to the larger picture of BDNF epigenetics and 
cognitive ageing. 
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These findings highlight the potential for further understanding of BDNF regulation, with 
implications for both cognitive ageing, and the development and progression of AD. As 
described, further investigation should be performed into the individual lines of research, 
but if they support the findings of this study, then BDNF should be considered as part of 
an underlying biomarker framework for the neurological changes that could prelude AD.  
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